

Edgar Filing: PharMerica CORP - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

| Class of Common Stock | Outstanding at October 30, 2015 |
|--------------------------------|---------------------------------|
| Common stock, \$0.01 par value | 30,454,732 shares |

PHARMERICA CORPORATION
FORM 10-Q
TABLE OF CONTENTS

| | Page |
|--|------|
| PART I. FINANCIAL INFORMATION | |
| Item 1. Financial Statements (Unaudited) | |
| <u>Condensed Consolidated Statements of Operations - For the Three and Nine Months Ended September 30, 2014 and 2015</u> | 3 |
| <u>Condensed Consolidated Balance Sheets - As of December 31, 2014 (As Adjusted) and September 30, 2015</u> | 4 |
| <u>Condensed Consolidated Statements of Cash Flows - For the Three and Nine Months Ended September 30, 2014 and 2015</u> | 5 |
| <u>Condensed Consolidated Statement of Stockholders' Equity - For the Nine Months Ended September 30, 2015</u> | 6 |
| <u>Notes to Condensed Consolidated Financial Statements</u> | 7 |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 19 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 35 |
| Item 4. <u>Controls and Procedures</u> | 35 |
| PART II. OTHER INFORMATION | |
| Item 1. <u>Legal Proceedings</u> | 36 |
| Item 1A. <u>Risk Factors</u> | 36 |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 36 |
| Item 4. <u>Mine Safety Disclosures</u> | 36 |
| Item 6. <u>Exhibits</u> | 37 |
| <u>SIGNATURES</u> | 38 |
| <u>Exhibit Index</u> | 39 |

PHARMERICA CORPORATION

CONDENSED CONSOLIDATED INCOME STATEMENTS
 For the Three and Nine Months Ended September 30, 2014 and 2015
 (Unaudited)
 (In millions, except share and per share amounts)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|------------|------------------------------------|------------|
| | 2014 | 2015 | 2014 | 2015 |
| Revenues | \$470.2 | \$498.8 | \$1,371.0 | \$1,507.8 |
| Cost of goods sold | 387.2 | 420.2 | 1,126.1 | 1,259.4 |
| Gross profit | 83.0 | 78.6 | 244.9 | 248.4 |
| Selling, general and administrative expenses | 56.0 | 52.7 | 171.1 | 167.1 |
| Amortization expense | 4.9 | 7.0 | 13.6 | 20.6 |
| Merger, acquisition, integration costs and other charges | 3.8 | 8.0 | 10.3 | 15.2 |
| Settlement, litigation and other related charges | 1.1 | 2.1 | 28.9 | 11.3 |
| Restructuring and impairment charges | 0.1 | 0.2 | 3.2 | 0.3 |
| Hurricane Sandy disaster costs | - | 0.1 | 0.1 | 0.1 |
| Operating income | 17.1 | 8.5 | 17.7 | 33.8 |
| Interest expense, net | 2.1 | 2.1 | 6.9 | 5.4 |
| Loss on extinguishment of debt | 4.3 | - | 4.3 | - |
| Income before income taxes | 10.7 | 6.4 | 6.5 | 28.4 |
| Provision for income taxes | 2.2 | 3.4 | 2.9 | 13.5 |
| Net income | \$8.5 | \$3.0 | \$3.6 | \$14.9 |
| Earnings per common share: | | | | |
| Basic | \$0.28 | \$0.10 | \$0.12 | \$0.49 |
| Diluted | \$0.28 | \$0.10 | \$0.12 | \$0.48 |
| Shares used in computing earnings per common share: | | | | |
| Basic | 30,073,133 | 30,431,845 | 29,944,875 | 30,336,548 |
| Diluted | 30,595,302 | 30,896,294 | 30,502,928 | 30,798,834 |

See accompanying Notes to Condensed Consolidated Financial Statements

3

PHARMERICA CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

As of December 31, 2014 and September 30, 2015

(Unaudited)

(In millions, except share and per share amounts)

| | (As Adjusted) | |
|--|------------------|------------|
| | December | September |
| | 31, 2014 | 30, 2015 |
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 33.3 | \$ 40.0 |
| Accounts receivable, net | 195.4 | 195.8 |
| Inventory | 135.5 | 117.5 |
| Deferred tax assets, net | 42.8 | 37.2 |
| Income taxes receivable | - | 9.2 |
| Prepays and other assets | 90.3 | 52.6 |
| | 497.3 | 452.3 |
| Equipment and leasehold improvements | 196.4 | 210.3 |
| Accumulated depreciation | (125.0) | (138.8) |
| | 71.4 | 71.5 |
| Goodwill | 323.6 | 341.8 |
| Intangible assets, net | 177.6 | 165.2 |
| Other | 4.1 | 29.2 |
| | \$ 1,074.0 | \$ 1,060.0 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Current liabilities: | | |
| Accounts payable | \$ 96.0 | \$ 83.3 |
| Salaries, wages and other compensation | 35.1 | 34.3 |
| Current portion of long-term debt | 6.3 | 11.4 |
| Income taxes payable | 2.3 | - |
| Other accrued liabilities | 38.5 | 38.2 |
| | 178.2 | 167.2 |
| Long-term debt | 344.4 | 326.0 |
| Other long-term liabilities | 57.6 | 55.7 |
| Deferred tax liabilities | 15.7 | 14.2 |
| Commitments and contingencies (See Note 5) | | |
| Stockholders' equity: | | |
| Preferred stock, \$0.01 par value per share; 1,000,000 shares authorized and no shares issued, December 31, 2014 and September 30, 2015 | - | - |
| | 0.3 | 0.3 |

Edgar Filing: PharMerica CORP - Form 10-Q

| | | |
|---|------------|------------|
| Common stock, \$0.01 par value per share; 175,000,000 shares authorized; 32,725,786 and 33,227,551 shares issued as of December 31, 2014 and September 30, 2015, respectively | | |
| Capital in excess of par value | 394.1 | 402.3 |
| Retained earnings | 117.0 | 131.9 |
| Treasury stock at cost, 2,617,305 and 2,774,268 shares at December 31, 2014 and September 30, 2015, respectively | (33.3) | (37.6) |
| | 478.1 | 496.9 |
| | \$ 1,074.0 | \$ 1,060.0 |

See accompanying Notes to Condensed Consolidated Financial Statements

4

PHARMERICA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Three and Nine Months Ended September 30, 2014 and 2015

(Unaudited)

(In millions)

| | Three Months Ended September 30, 2014 | | Nine Months Ended September 30, 2015 | |
|---|--|--------|---|--------|
| Cash flows provided by (used in) operating activities: | | | | |
| Net income | \$8.5 | \$3.0 | \$3.6 | \$14.9 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | | | | |
| Depreciation | 4.9 | 5.7 | 14.5 | 17.2 |
| Amortization | 4.9 | 7.0 | 13.6 | 20.6 |
| Merger, acquisition, integration costs and other charges | - | - | 2.5 | - |
| Stock-based compensation and deferred compensation | 1.8 | 1.7 | 5.7 | 5.4 |
| Amortization of deferred financing fees | 0.5 | 0.1 | 1.8 | 0.4 |
| Deferred income taxes | (4.0) | 2.1 | (3.3) | 4.6 |
| (Gain) Loss on disposition of equipment | - | - | (0.1) | 0.1 |
| Loss (Gain) on acquisition/disposition | 0.1 | - | (0.2) | - |
| Loss on debt extinguishment | 4.3 | - | 4.3 | - |
| Other | - | - | 0.1 | 0.1 |
| Change in operating assets and liabilities: | | | | |
| Accounts receivable, net | (1.7) | 3.4 | 10.4 | 1.2 |
| Inventory | 14.9 | 17.5 | (16.3) | 18.1 |
| Prepays and other assets | (15.1) | (7.7) | (26.2) | 12.3 |
| Accounts payable | (2.4) | 3.6 | (22.9) | (11.9) |
| Salaries, wages and other compensation | 5.2 | 2.1 | (2.7) | (0.9) |
| Other accrued and long-term liabilities | (5.7) | 0.2 | 16.6 | (10.2) |
| Change in income taxes payable (receivable) | 3.7 | (1.0) | (0.4) | (10.0) |
| Excess tax benefit from stock-based compensation | (0.2) | (0.2) | (3.4) | (2.3) |
| Net cash provided by (used in) operating activities | 19.7 | 37.5 | (2.4) | 59.6 |
| Cash flows provided by (used in) investing activities: | | | | |
| Purchase of equipment and leasehold improvements | (6.2) | (6.6) | (19.0) | (17.6) |
| Acquisitions, net of cash acquired | (107.2) | (0.3) | (124.8) | (20.9) |
| Cash proceeds from the sale of assets | - | 0.1 | 0.1 | 0.2 |
| Cash proceeds from dispositions | - | - | 0.4 | - |
| Net cash used in investing activities | (113.4) | (6.8) | (143.3) | (38.3) |
| Cash flows provided by (used in) financing activities: | | | | |
| Repayments of long-term debt | (225.0) | (2.8) | (231.3) | (2.8) |

Edgar Filing: PharMerica CORP - Form 10-Q

| | | | | |
|---|--------|--------|---------|--------|
| Borrowing of long-term debt | 225.0 | - | 225.0 | - |
| Net activity of long-term revolving credit facility | 92.0 | (9.0) | 135.9 | (10.0) |
| Payment of debt issuance costs | (2.7) | - | (2.7) | - |
| Issuance of common stock | 0.4 | - | 3.4 | 0.7 |
| Purchase of treasury stock | (0.2) | (0.4) | (5.1) | (4.3) |
| Excess tax benefit from stock-based compensation | 0.2 | 0.2 | 3.4 | 2.3 |
| Repayments of capital lease obligations | - | - | - | (0.5) |
| Net cash provided by (used in) financing activities | 89.7 | (12.0) | 128.6 | (14.6) |
| | | | | |
| Change in cash and cash equivalents | (4.0) | 18.7 | (17.1) | 6.7 |
| Cash and cash equivalents at beginning of period | 11.1 | 21.3 | 24.2 | 33.3 |
| | | | | |
| Cash and cash equivalents at end of period | \$7.1 | \$40.0 | \$7.1 | \$40.0 |
| | | | | |
| Supplemental information: | | | | |
| Cash paid for interest | \$1.9 | \$3.2 | \$5.6 | \$6.2 |
| Cash paid for taxes | \$1.0 | \$2.4 | \$5.7 | \$19.4 |

See accompanying Notes to Condensed Consolidated Financial Statements

5

PHARMERICA CORPORATION

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

For the Nine Months Ended September 30, 2015

(Unaudited)

(In millions, except share amounts)

| | Common Stock | | Capital in Excess of Par | Retained Earnings | Treasury Stock | Total |
|--|--------------|--------|--------------------------------------|----------------------|-------------------|----------|
| | Shares | Amount | Value | | | |
| Balance at December 31, 2014 | 30,108,481 | \$ 0.3 | \$ 394.1 | \$ 117.0 | \$ (33.3) | \$ 478.1 |
| Net income | | | | 14.9 | | 14.9 |
| Exercise of stock options and tax components of stock-based awards, net | 139,133 | - | 2.8 | - | - | 2.8 |
| Vested restricted stock units | 219,625 | - | - | - | - | - |
| Vested performance stock units | 143,007 | - | - | - | - | - |
| Treasury stock at cost | (156,963) | - | - | - | (4.3) | (4.3) |
| Stock-based compensation - non-vested restricted stock | - | - | 5.3 | - | - | 5.3 |
| Stock-based compensation - stock options | - | - | 0.1 | - | - | 0.1 |
| Balance at September 30, 2015 | 30,453,283 | \$ 0.3 | \$ 402.3 | \$ 131.9 | \$ (37.6) | \$ 496.9 |

See accompanying Notes to Condensed Consolidated Financial Statements

6

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

PharMerica Corporation together with its subsidiaries (the "Corporation"), is a leading provider of pharmacy services. The Corporation serves the long-term care, hospital pharmacy management services, specialty home infusion and specialty oncology pharmacy markets. The Corporation operates 94 institutional pharmacies, 15 specialty home infusion pharmacies, and 5 specialty oncology pharmacies in 45 states. The Corporation's customers are institutional healthcare providers, such as skilled nursing facilities, assisted living facilities, hospitals, individuals receiving in-home care and patients with cancer.

Operating Segments

The Corporation consists of three operating segments: institutional pharmacy, specialty infusion services and specialty oncology pharmacy. Management believes the nature of the products and services are similar, the payers for the products and services are common among the segments and all segments operate in the healthcare regulatory environment. In addition, the segments are economically similar. Accordingly, management has aggregated the three operating segments into one reporting segment.

Principles of Consolidation

All intercompany transactions have been eliminated.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and disclosures required by generally accepted accounting principles in the United States ("U.S. GAAP") for complete financial statements. Accordingly, the accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Corporation and related footnotes for the year ended December 31, 2014, included in the Corporation's Annual Report on Form 10-K. The balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements adjusted for acquisition related measurement period adjustments.

The results of operations for the interim periods are not necessarily indicative of results of operations for a full year. It is the opinion of management that all necessary adjustments for a fair presentation of the condensed consolidated financial statements for the interim periods have been made and are of a normal recurring nature.

Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the

reported amounts of revenues and expenses during the reporting periods. Significant estimates are involved in collectability of accounts receivable, revenue recognition, inventory valuation, supplier rebates, the valuation of long-lived assets and goodwill, and accounting for income taxes. Actual amounts may differ from these estimates.

Fair Value of Financial Instruments

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Corporation follows a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs for which there is little or no market data, which require the Corporation to develop its own assumptions.

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:

A. Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

B. Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

C. Income approach: Techniques to convert future amounts to a single present amount based upon market expectations (including present value techniques, option-pricing and excess earnings models).

7

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The financial liabilities recorded at fair value at December 31, 2014 and September 30, 2015 are set forth in the tables below (dollars in millions):

| As of December 31, 2014 | Liability | Level 1 | Level 2 | Level 3 | Valuation Technique |
|---------------------------------|-----------|---------|----------|---------|---------------------|
| Financial Liability | | | | | |
| Deferred Compensation Plan | \$ (8.0) | \$ - | \$ (8.0) | \$ - | A |
| Contingent Consideration | (1.1) | - | - | (1.1) | C |
| Mandatorily Redeemable Interest | (8.3) | - | - | (8.3) | C |

| As of September 30, 2015 | Liability | Level 1 | Level 2 | Level 3 | Valuation Technique |
|---------------------------------|-----------|---------|----------|---------|---------------------|
| Financial Liability | | | | | |
| Deferred Compensation Plan | \$ (7.9) | \$ - | \$ (7.9) | \$ - | A |
| Contingent Considerations | (9.0) | - | - | (9.0) | C |
| Mandatorily Redeemable Interest | (7.0) | - | - | (7.0) | C |

The deferred compensation plan liability represents an unfunded obligation associated with the deferred compensation plan offered to eligible employees and members of the Board of Directors of the Corporation. The fair value of the liability associated with the deferred compensation plan is derived using pricing and other relevant information for investments in phantom shares of certain available investment options, primarily mutual funds. This liability is classified as other long-term liabilities in the accompanying condensed consolidated balance sheets.

The contingent consideration represents future earn-outs associated with the Corporation's acquisition of an institutional pharmacy business purchased in 2013 and two infusion businesses purchased in 2014 and 2015. The fair values of the liabilities associated with the contingent consideration were derived using the income approach with unobservable inputs, which included future gross profit forecasts and present value assumptions, and there was little or no market data. The Corporation assessed the fair values of the liabilities as of the acquisition date and will assess quarterly thereafter until settlement. These liabilities are classified as current and other long-term liabilities in the accompanying condensed consolidated balance sheets.

The mandatorily redeemable interest represents a future obligation associated with the Corporation's acquisition of a specialty pharmacy business, OncoMed Specialty, LLC ("Onco"), purchased on December 6, 2013. The mandatorily redeemable interest is classified as a long-term liability and measured at fair value. The fair value was derived using the income approach with unobservable inputs, which included a future gross profit forecast and present value assumptions, and there was little or no market data. The Corporation assessed and adjusted the mandatorily redeemable interest's fair value of the liability at September 30, 2015.

For the year ended December 31, 2014 and the nine months ended September 30, 2015, there were no transfers between the valuation hierarchy Levels 1, 2, and 3. The following table summarizes the change in fair value of the Corporation's contingent consideration and mandatorily redeemable interest identified as Level 3 for the year ended December 31, 2014 and the nine months ended September 30, 2015 (in millions):

Edgar Filing: PharMerica CORP - Form 10-Q

| | Contingent Consideration | | Mandatorily Redeemable Interest |
|--------------------------------------|-----------------------------|---|---------------------------------------|
| Beginning balance, December 31, 2013 | \$ 0.7 | | \$ 8.2 |
| Additions from business acquisitions | 1.1 | | - |
| Change in fair value | (0.7 |) | 0.1 |
| Balance, December 31, 2014 | 1.1 | | 8.3 |
| Additions from business acquisitions | 7.9 | | - |
| Change in fair value | - | | (1.3) |
| Balance, September 30, 2015 | \$ 9.0 | | \$ 7.0 |

The carrying amounts reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, inventory and accounts payable approximate fair value because of the short-term maturity of these instruments. The carrying amount of the Corporation's debt approximates fair value due to the interest being set at variable market interest rates (Level 2).

8

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable primarily consist of amounts due from Prescription Drug Plans ("PDPs") under Medicare Part D, institutional healthcare providers, the respective state Medicaid programs, third party insurance companies, and private payers. The Corporation's ability to collect outstanding receivables is critical to its results of operations and cash flows. To provide for accounts receivable that could become uncollectible in the future, the Corporation establishes an allowance for doubtful accounts to reduce the carrying value of such receivables to the extent it is probable that a portion or all of a particular account will not be collected.

The Corporation has an established a process to determine the adequacy of the allowance for doubtful accounts, which relies on analytical tools, specific identification, and benchmarks to arrive at a reasonable allowance. No single statistic or measurement determines the adequacy of the allowance for doubtful accounts. The Corporation monitors and reviews trends by payer classification along with the composition of the Corporation's aging accounts receivable. This review is focused primarily on trends in private and other payers, PDP's, dual eligible co-payments, historic payment patterns of long-term care institutions, and monitoring respective credit risks. In addition, the Corporation analyzes other factors such as revenue days in accounts receivables, denial trends by payer types, payment patterns by payer types, subsequent cash collections, and current events that may impact payment patterns of the Corporation's long-term care institutional customers. Accounts receivable are written off after collection efforts have been completed in accordance with the Corporation's policies.

The Corporation's accounts receivable and summarized aging categories are as follows (dollars in millions):

| | (As Adjusted) | | | |
|------------------------------------|---------------|-----------|-------|---|
| | December | September | | |
| | 31, | 30, | | |
| | 2014 | 2015 | | |
| Institutional healthcare providers | \$ 153.2 | \$ 157.3 | | |
| Medicare Part D | 30.5 | 27.4 | | |
| Private payer and other | 30.6 | 30.2 | | |
| Insured | 24.5 | 25.4 | | |
| Medicaid | 11.7 | 10.0 | | |
| Medicare | 3.0 | 3.2 | | |
| Allowance for doubtful accounts | (58.1) | (57.7) | | |
| | \$ 195.4 | \$ 195.8 | | |
| 0 to 60 days | 58.8 | % | 58.9 | % |
| 61 to 120 days | 17.2 | % | 15.2 | % |
| Over 120 days | 24.0 | % | 25.9 | % |
| | 100.0 | % | 100.0 | % |

The following is a summary of activity in the Corporation's allowance for doubtful accounts (dollars in millions):

| | Charges to Costs | | | |
|--------------------------------------|--------------------------|----------|------------|-------------------|
| | Beginning and Balance | Expenses | Write-offs | Ending Balance |
| Allowance for doubtful accounts: | | | | |
| Year ended December 31, 2014 | \$ 56.7 | \$ 23.2 | \$ (21.8) | \$ 58.1 |
| Nine months ended September 30, 2015 | \$ 58.1 | \$ 9.5 | \$ (9.9) | \$ 57.7 |

Goodwill and Other Intangibles

The Corporation's policy is to perform a quantitative assessment of its institutional pharmacy and specialty infusion reporting units to determine whether it is more likely than not (defined as having a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount. The Corporation performed a quantitative assessment as of December 31, 2014. The fair values of the institutional pharmacy and specialty infusion reporting units as calculated for the analysis were approximately 48.2% and 13.1%, respectively, greater than book value as of December 31, 2014. The Corporation also performed a qualitative assessment of its specialty oncology reporting unit as of December 31, 2014 and did not find it necessary to perform the first step of the two-step impairment test based on that analysis.

There were no impairment triggering events during the nine months ended September 30, 2015.

The Corporation's finite-lived intangible assets are comprised primarily of trade names, customer relationship assets, limited distributor relationships, doctor and insurer relationships and non-compete agreements. Finite-lived intangible assets are amortized on a straight-line basis over the course of their lives ranging from 5 to 20 years. For impairment reviews, intangible assets are reviewed on a specific pharmacy basis or as a group of pharmacies depending on the intangible assets under review. The Corporation's goodwill and intangible assets are further described in Note 3.

Restructuring and Impairment Charges

Restructuring and impairment charges in the condensed consolidated financial statements represent amounts expensed for purposes of realigning corporate and pharmacy locations.

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 1—ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Mandatorily Redeemable Interest

The Corporation acquired 37.5% of the membership interests of Onco while also obtaining control of the business. The subsidiary is consolidated in the Corporation's condensed consolidated financial statements and the mandatorily redeemable interest is classified as debt within other long-term liabilities in the condensed consolidated balance sheets.

Measurement Period Adjustments

For the nine months ended September 30, 2015, the Corporation has adjusted certain amounts on the condensed consolidated balance sheet as of December 31, 2014 as a result of measurement period adjustments related to acquisitions completed in the prior year (See Note 2).

NOTE 2—ACQUISITIONS

2015 Acquisition

The Corporation through its wholly owned subsidiary, Amerita, acquired Coastal Pharmaceutical Services Corporation ("InfusionRx Acquisition") on January 28, 2015. The InfusionRx Acquisition had an estimated purchase price of \$27.9 million, comprised of a net cash payment of \$20.0 million and an estimated fair value of contingent consideration of \$7.9 million. The resulting amount of goodwill and identifiable intangibles related to this transaction in the aggregate were \$18.1 million and \$8.2 million, respectively. The Corporation believes the resulting amount of goodwill reflects its expectation of synergistic benefits of the acquisition. Tax deductible goodwill associated with the acquisition was \$18.1 million as of September 30, 2015. The net assets and operating results of the acquisition have been included in the Corporation's condensed consolidated financial statements from the date of acquisition.

2014 Acquisitions

During the year ended December 31, 2014, the Corporation completed acquisitions of four long-term care businesses and one infusion business (collectively the "2014 Acquisitions"), none of which were individually significant to the Corporation. The 2014 Acquisitions required cash payments of approximately \$115.2 million in the aggregate. The resulting amount of goodwill and identifiable intangibles related to these transactions in the aggregate were \$40.9 million and \$61.4 million, respectively. The Corporation believes the resulting amount of goodwill reflects its expectation of synergistic benefits of the acquisitions. Tax deductible goodwill associated with the 2014 Acquisitions was \$30.7 million as of September 30, 2015. The net assets and operating results of the 2014 Acquisitions have been included in the Corporation's condensed consolidated financial statements from their respective dates of acquisition.

Amounts contingently payable related to the 2014 Acquisitions, representing payments originating from an earn-out provision of the infusion acquisition, were \$1.1 million as of December 31, 2014 and September 30, 2015.

The amounts recognized as of the acquisition dates for the 2014 Acquisitions, on a combined basis, for assets acquired and liabilities assumed are as follows (dollars in millions):

| | Amounts Recognized as of Acquisition Date | Measurement Period Adjustments | As Adjusted |
|--|---|--------------------------------------|----------------|
| Accounts receivable | \$ 26.7 | \$ (0.3) | \$ 26.4 |
| Inventory | 6.8 | (0.2) | 6.6 |
| Deferred tax assets – current | 1.8 | - | 1.8 |
| Other current assets | 3.1 | (0.1) | 3.0 |
| Equipment and leasehold improvements | 4.8 | - | 4.8 |
| Deferred tax assets | 8.2 | (3.5) | 4.7 |
| Identifiable intangibles | 61.4 | - | 61.4 |
| Goodwill | 34.9 | 6.0 | 40.9 |
| Total Assets | 147.7 | 1.9 | 149.6 |
| Current liabilities | 26.4 | 1.6 | 28.0 |
| Other long-term liabilities | 6.9 | (0.5) | 6.4 |
| Total Liabilities | 33.3 | 1.1 | 34.4 |
| Total purchase price, less cash acquired | \$ 114.4 | \$ 0.8 | \$ 115.2 |

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 2—ACQUISITIONS (Continued)

Pro forma financial statements are not presented on the 2014 and 2015 acquisitions as the results are not material to the Corporation's condensed consolidated financial statements.

Other

For the three months ended September 30, 2014 and September 30, 2015, the Corporation incurred \$3.7 million and \$7.6 million, respectively, and \$10.0 million and \$14.7 million for the nine months ended September 30, 2014 and September 30, 2015, respectively, of acquisition-related costs, which have been classified as a component of merger, acquisition, integration costs and other charges.

NOTE 3—GOODWILL AND INTANGIBLES

As of December 31, 2014 (as adjusted) and September 30, 2015 the carrying amount of goodwill was \$323.6 million and \$341.8 million, respectively.

The following table presents the components of the Corporation's finite lived intangible assets (dollars in millions):

| | Balance at December | Additions | Balance at September |
|--------------------------------|---------------------------|------------|-------------------------|
| Finite Lived Intangible Assets | 31, 2014 | | 30, 2015 |
| Customer relationships | \$ 177.5 | \$ 7.0 | \$ 184.5 |
| Trade name | 62.2 | 0.6 | 62.8 |
| Non-compete agreements | 19.9 | 0.6 | 20.5 |
| Sub Total | 259.6 | 8.2 | 267.8 |
| Accumulated amortization | (82.0) | (20.6) | (102.6) |
| Net intangible assets | \$ 177.6 | \$ (12.4) | \$ 165.2 |

Amortization expense relating to finite-lived intangible assets was \$4.9 million and \$7.0 million for the three months ended September 30, 2014 and 2015, respectively. Amortization expense relating to finite-lived intangible assets was \$13.6 million and \$20.6 million for the nine months ended September 30, 2014 and 2015, respectively.

NOTE 4—CREDIT AGREEMENT

On September 17, 2014, the Corporation entered into a credit agreement by and among the Corporation, the lenders named therein (the "Lenders"), Bank of America, N.A., as administrative agent, JP Morgan Chase Bank N.A., as syndication agent, and U.S. Bank, National Association, Citibank, N.A., MUFG Union Bank, N.A., BBVA Compass Bank and SunTrust Bank as co-documentation agents (the "Credit Agreement"). The Credit Agreement consists of a \$225.0 million term loan facility and a \$310.0 million revolving credit facility. The terms and conditions of the Credit Agreement are customary to facilities of this nature.

Edgar Filing: PharMerica CORP - Form 10-Q

As of September 30, 2015, \$222.2 million was outstanding under the term loan facility and \$115.0 million was outstanding under the revolving credit facility. Indebtedness under the Credit Agreement matures on September 17, 2019, at which time the commitments of the Lenders to make revolving loans also expire.

The table below summarizes the total outstanding debt of the Corporation (dollars in millions):

| | December 31, 2014 | September 30, 2015 |
|--|----------------------|-----------------------|
| Term Debt - payable to lenders at LIBOR plus applicable margin (2.19% as of September 30, 2015), matures September 17, 2019 | \$ 225.0 | \$ 222.2 |
| Revolving Credit Facility payable to lenders, interest at LIBOR plus applicable margin (2.15% of September 30, 2015), matures September 17, 2019 | 125.0 | 115.0 |
| Capital lease obligations | 0.7 | 0.2 |
| Total debt | 350.7 | 337.4 |
| Less: Current portion of long-term debt | 6.3 | 11.4 |
| Total long-term debt | \$ 344.4 | \$ 326.0 |

The Corporation's indebtedness has the following maturities as of September 30, 2015 (dollars in millions):

| Year Ending December 31, | Term Debt | Revolving Credit Facility | Capital Lease Obligations | Total Maturities |
|--------------------------|--------------|---------------------------------|---------------------------------|---------------------|
| 2015 | \$2.8 | \$ - | \$ 0.2 | \$ 3.0 |
| 2016 | 11.3 | - | - | 11.3 |
| 2017 | 11.3 | - | - | 11.3 |
| 2018 | 11.3 | - | - | 11.3 |
| 2019 | 185.5 | 115.0 | - | 300.5 |
| | \$222.2 | \$ 115.0 | \$ 0.2 | \$ 337.4 |

11

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 4—CREDIT AGREEMENT (Continued)

The Credit Agreement provides for the issuance of letters of credit which, when issued, reduce availability under the revolving credit facility. The aggregate amount of letters of credit outstanding as of September 30, 2015 was \$3.0 million. After giving effect to the letters of credit, total availability under the revolving credit facility was \$192.0 million as of September 30, 2015.

NOTE 5—COMMITMENTS AND CONTINGENCIES

Legal Action and Regulatory

The Corporation maintains liabilities for certain of its outstanding investigations and litigation. In accordance with the provisions of U.S. GAAP for contingencies, the Corporation records a liability when it is probable that such a liability has been incurred and the amount of the loss can be reasonably estimated. To the extent that the resolution of contingencies result in actual losses that differ from the Corporation's recorded liabilities, earnings will be charged or credited accordingly. The Corporation cannot know the ultimate outcome of the pending matters described below, and there can be no assurance that the resolution of these matters will not have a material adverse impact on the Corporation's consolidated results of operations, financial position or cash flows. As a part of its ongoing operations, the Corporation is subject to various inspections, audits, inquiries, investigations and similar actions by third parties, as well as by government/regulatory authorities responsible for enforcing the laws and regulations to which the Corporation is subject. Further, under the federal False Claims Act, private parties have the right to bring qui tam, or "whistleblower," suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. The inherently unpredictable nature of legal proceedings may be impacted by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) significant facts are in dispute; (vi) a large number of parties are participating in the proceedings (including where it is uncertain how liability, if any, will be shared among defendants); or (vii) the proceedings present a wide range of potential outcomes.

The Corporation is the subject of certain investigations and is a defendant in a number of cases, including those discussed below.

On October 29, 2013, a complaint was filed in the United States District Court for the Southern District of Florida by Pines Nursing Homes (77), Inc. as a putative class action against the Corporation. The complaint alleged that the Corporation sent unsolicited advertisements promoting the Corporation's goods or services by facsimile to individuals or entities, and that such communications did not include an opt-out clause, all in violation of the federal Telephone Consumer Protection Act ("TCPA"). The Complaint did not specify the amount of damages sought, but the TCPA provides a statutory remedy of \$500 per facsimile communication sent in violation of the statute, which may be trebled in the event of a willful violation. On August 18, 2014, the Corporation entered into a Settlement Agreement with the putative class and class counsel resolving all claims raised in the complaint. The parties moved on September 8, 2014 for, among other things, certification of the putative class for the purposes of effectuating the settlement and preliminary approval of the parties' settlement, and have requested a hearing on that motion. On June 26, 2015 the court granted the Joint Motion for Preliminary Approval of the parties settlement and the court has scheduled the final approval hearing for November 12, 2015.

On November 20, 2013 a complaint filed by a relator, Robert Gadbois, on behalf of the U.S. Government and various state governments, was unsealed by the United States District for the District of Rhode Island against the Corporation alleging that the Corporation dispensed controlled and non-controlled substances in violation of the CSA and that, as a result, the dispenses were not eligible for payment and that the claims the Corporation submitted to the Government were false within the meaning of the FCA. The U.S. Government and the various state governments declined to intervene in this case. On October 3, 2014, the Corporation's motion to dismiss was granted by the court. The relator has appealed the court's decision. The Corporation intends to continue to defend the case vigorously.

On March 4, 2011, a relator, Mark Silver, on behalf of the U.S. Government and various state governments, filed a complaint in the United States District Court for the District of New Jersey against the Corporation alleging that the Corporation violated the FCA and Federal Anti-Kickback Statute through its agreements to provide prescription drugs to nursing homes under certain Medicare and Medicaid programs. On February 19, 2013, the U.S. Government declined to intervene in the case. The complaint has been amended several times, most recently on November 12, 2013, and thereafter served upon the Corporation. On December 6, 2013, the Corporation moved to dismiss the amended complaint for failure to state a claim upon which relief may be granted and on September 29, 2014, the court declined to dismiss the case, but limited the relevant time period for which claims could be brought against the Corporation. The Corporation intends to vigorously defend itself against these allegations.

12

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 5—COMMITMENTS AND CONTINGENCIES (Continued)

On January 31, 2014, a relator, Frank Kurnik, on behalf of the U.S. Government and various state governments served its complaint filed in the United States District for the District of South Carolina alleging that the Corporation solicited and received remuneration in violation of the Federal Anti-Kickback Statute from drug manufacturer Amgen in exchange for preferring and promoting Amgen's drug Aranesp over a competing drug called Procrit. The U.S. Government and the various states declined to intervene in the case. On April 7, 2014, the Corporation moved to dismiss the complaint and on July 23, 2014, the motion was denied. On January 13, 2015, the Corporation again moved to dismiss the complaint and on March 23, 2015, the second motion was denied. On April 2, 2015, the Corporation moved the court to reconsider its denial of the second motion to dismiss and that motion was denied. The Corporation intends to vigorously defend itself against these allegations.

The U.S. Department of Justice, through the U.S. Attorney's Office for the Western District of Virginia, investigated whether the Company's activities in connection with the agreements it had with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. The Company cooperated with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter. On May 29, 2014, the United States District Court for the Western District of Virginia entered an order unsealing two previously partially sealed qui tam complaints, entitled United States, et al., ex rel. Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp., No. 1:07-cv-00006 and United States, et al., ex rel. McCoyd v. Abbott Laboratories, Omnicare, Inc., PharMerica Corp., and Miles White, No. 1:07-cv-0008. The Corporation entered into a settlement agreement on October 6, 2015 with the Government including the Department of Justice, with approvals from the National Association of Medicaid Fraud Control and the Department of Health and Human Services Office of Inspector General. In the settlement, the Corporation agreed to pay \$9.3 million to resolve the matter which was previously accrued for in the condensed consolidated balance sheet of the Corporation.

On September 10, 2014, the Corporation filed a Complaint in Jefferson Circuit Court in Louisville, Kentucky against AmerisourceBergen Drug Corporation ("ABDC") for failure of ABDC to comply with certain pricing and rebate provisions of the Amended Prime Vendor Agreement ("Amended PVA"). The Corporation subsequently filed a First Amended Verified Complaint on September 26, 2014 asserting additional breaches of the Amended PVA.

As a result of ABDC's failure to comply with certain pricing and rebate provisions, the Corporation had recorded a receivable of \$40.8 million related to these disputes at December 31, 2014. Separately, as of December 31, 2014, the Corporation had recorded \$12.2 million for additional rebates owing from ABDC which at that time the Corporation believed were not in dispute and had previously been paid by ABDC in all the prior quarters. All these receivables totaled \$53.0 million and were included in prepaids and other assets in the accompanying condensed consolidated balance sheet as of December 31, 2014. During the period of January 1, 2015 through March 31, 2015, an additional \$18.5 million, net of payments received, of certain rebates and guarantees owed by ABDC under the Amended PVA were recognized which brought the total receivable to \$71.5 million at March 31, 2015 and September 30, 2015.

On March, 2, 2015, the Corporation notified ABDC of its intent to terminate the Amended PVA effective April 1, 2015. The Corporation also announced that it had entered into a Prime Vendor Agreement with Cardinal Health ("Cardinal") effective April 1, 2015. On March 3, 2015, the Corporation received a letter from ABDC terminating the Amended PVA effective immediately based upon the Corporation's alleged failure to pay certain disputed miscellaneous charges and the Corporation's signing of the Cardinal PVA. The Corporation believes ABDC did not have the right to immediately terminate the contract pursuant to the terms of the Amended PVA. On March 6 and

March 13, 2015, the Corporation withheld from ABDC normal recurring payments for drug purchases of approximately \$48.8 million.

The following table represents all receivables, whether previously disputed or not, due and owing from ABDC at September 30, 2015 and the related amounts allegedly payable to ABDC, which have been offset resulting in a net receivable at September 30, 2015 of \$22.7 million. This net receivable is included in other assets in the accompanying condensed consolidated balance sheet as of September 30, 2015.

Presented in the condensed consolidated balance sheet, the following amounts are offset as of September 30, 2015 (in millions):

| Description | Gross Amount of Recognized Asset | Gross Liability Offset in the Condensed Consolidated Balance Sheet | Net Amount of Asset Presented in the Condensed Consolidated Balance Sheet |
|-----------------------------|----------------------------------|--|---|
| Rebates & Other Receivables | \$ 71.5 | \$ (48.8) | \$ 22.7 |
| Total | \$ 71.5 | \$ (48.8) | \$ 22.7 |

The Corporation will have claims for additional damages resulting from ABDC's breaches of the Amended PVA. The Corporation intends to vigorously pursue its claims. At this time, the Corporation is unable to determine the ultimate impact of these litigation proceedings on its consolidated financial condition, results of operations, or liquidity. The litigation with ABDC could continue for an extended period of time, likely longer than 12 months. The Corporation cannot provide any assurances about the outcome of the litigation.

In addition, the Corporation is involved in certain legal actions and regulatory investigations arising in the ordinary course of business.

At September 30, 2015, the Corporation had accrued approximately \$39.9 million in the aggregate related to the legal actions and investigations.

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 5—COMMITMENTS AND CONTINGENCIES (Continued)

California Medicaid

On August 14, 2013, the California Department of Health Care Service ("DHCS") announced its intent to implement a ten percent (10%) reimbursement reduction for numerous healthcare providers, including long term care pharmacies.

The DHCS implemented the reduction prospectively beginning in the first quarter of 2014. In addition, the DHCS implemented, beginning October 2015, recouping a percentage of provider payments representing a ten percent (10%) reduction on certain drug reimbursements retroactive to June 1, 2011 through February 6, 2014. The Corporation has previously recorded a \$3.3 million liability and reduction of revenue for the expected amount of recoveries from June 1, 2011 through December 31, 2013.

NOTE 6—MERGER, ACQUISITION, INTEGRATION COSTS AND OTHER CHARGES

Merger, acquisition, integration costs and other charges combined were \$3.8 million and \$8.0 million for the three months ended September 30, 2014 and 2015, respectively, and \$10.3 million and \$15.2 million for the nine months ended September 30, 2014 and 2015, respectively.

Merger, integration costs and other charges for the three months ended September 30, 2014 and 2015 were \$0.1 million and \$0.4 million, respectively, and \$0.3 million and \$0.5 million for the nine months ended September 30, 2014 and 2015, respectively.

Acquisition related costs for the three months ended September 30, 2014 and 2015 were \$3.7 million and \$7.6 million, respectively, and \$10.0 million and \$14.7 million for the nine months ended September 30, 2014 and 2015, respectively.

NOTE 7—RESTRUCTURING COSTS AND OTHER CHARGES

In July 2013, the Corporation commenced the implementation of its restructuring plan as a result of the loss of two of the Corporation's significant customers, Kindred Healthcare ("Kindred") and Golden Living. The plan is a major initiative primarily designed to optimize operational efficiency while ensuring that the Corporation remains well-positioned to serve its clients and achieve sustainable, long-term growth. The Corporation's restructuring plan includes steps to right size its cost structure by adjusting its workforce and facility plans to reflect anticipated business needs. In addition, in the third quarter ended September 30, 2015, the Corporation began a restructuring and centralization initiative related to its specialty pharmacy business. The initiative is not expected to be material to the financial statements.

The Corporation recorded restructuring costs and other related charges of approximately of \$0.1 million and \$0.2 million during the three months ended September 30, 2014 and 2015, respectively, and \$3.2 million and \$0.3 million for the nine months ended September 30, 2014 and 2015, respectively. The restructuring charges primarily included severance pay, the buy-out of employment agreements, lease terminations, and other exit-related asset disposals, professional fees and facility exit costs.

The following table presents the components of the Corporation's restructuring liability (dollars in millions):

| | Balance | | | Balance at |
|--------------------------------------|----------|---------|-----------|------------|
| | at | | Utilized | September |
| | December | Accrual | Amounts | 30, 2015 |
| | 31, 2014 | | | |
| Employee Severance and related costs | \$ 0.3 | \$ 0.3 | \$ (0.6) | \$ - |
| Facility costs | 1.1 | - | (0.4) | 0.7 |
| | \$ 1.4 | \$ 0.3 | \$ (1.0) | \$ 0.7 |

The liability at September 30, 2015 represents amounts not yet paid relating to actions taken in connection with the restructuring plan (primarily lease payments and severance costs).

14

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 8—COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS

2015 Omnibus Incentive Plan

Effective April 29, 2015, the Corporation adopted the PharMerica Corporation 2015 Omnibus Incentive Plan (the "Omnibus Plan") under which the Corporation is authorized to grant equity-based and other awards to its employees, officers, directors, and consultants. The Omnibus Plan replaced the Amended and Restated PharMerica Corporation 2007 Omnibus Incentive Plan (the "Prior Plan").

The Corporation has reserved 2,000,000 shares of its common stock for awards to be granted under the Omnibus Plan, subject to certain increases and reductions for grants under the Prior Plan. The following shares shall be added back to the number of shares available for grant under the Omnibus Plan: (i) shares covered by an award that expire or are forfeited, canceled, surrendered, or otherwise terminated without the issuance of such shares; (ii) shares covered by an award that are settled only in cash; and (iii) shares withheld by the Corporation or any subsidiary to satisfy a tax withholding obligation with respect to full value awards granted pursuant to the Omnibus Plan. However, shares surrendered for the payment of the exercise price under stock options (or options outstanding under the Prior Plan), shares repurchased by us with option proceeds (or option proceeds under the Prior Plan), and shares withheld for taxes upon exercise or vesting of an award other than a full value award (or an award other than a full value award under the Prior Plan), will not again be available for issuance under the Omnibus Plan. In addition, if a stock appreciation right ("SAR") (or SAR under the Prior Plan) is exercised and settled in shares, all of the shares underlying the SAR will be counted against the Omnibus Plan limit regardless of the number of shares used to settle the SAR. The Omnibus Plan provides for certain limits on issuances of certain types of awards and awards to certain recipients. The Omnibus Plan prohibits share recycling for stock options and stock appreciation rights, meaning that shares used to pay the exercise price or tax withholding for those awards are not added back to the share reserve.

The Corporation's Compensation Committee administers the Omnibus Plan and has the authority to determine the recipient of the awards, the types of awards, the number of shares covered, and the terms and conditions of the awards. The Omnibus Plan allows for grants of incentive stock options, non-qualified stock options, stock appreciation rights, restricted share and restricted stock units, deferred shares, performance awards, including cash bonus awards, and other stock-based awards. The Corporation's Compensation Committee may condition the vesting, exercise or settlement of any award upon the achievement of one or more performance objectives.

Stock options granted to officers and employees under the Omnibus Plan generally vest in four equal annual installments and have a term of seven years. The restricted stock units granted to officers generally vest in three equal annual installments. The restricted stock units granted to members of the Board of Directors vest in one annual installment. The performance share units granted under the Omnibus Plan vest based upon the achievement of a target amount of the Corporation's adjusted earnings before interest, income taxes, depreciation and amortization, which reinforces the importance of achieving the Corporation's profitability objectives. The performance is generally measured over a three-year period.

As of September 30, 2015, total shares available for grants of stock-based awards pursuant to the Omnibus Plan were 1,851,155 shares.

Treasury Stock Purchases

In August 2010, the Board of Directors authorized a share repurchase of up to \$25.0 million of the Corporation's common stock, of which \$10.5 million was used. On July 2, 2012 the Board of Directors authorized an increase to the remaining portion of the existing share repurchase program that allows the Corporation to again repurchase up to a maximum of \$25.0 million of the Corporation's common stock. Approximately \$19.7 million remained available under the program as of September 30, 2015. Share repurchases under this authorization may be made in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and may be funded from available cash or the revolving credit facility. The amount and timing of the repurchases, if any, would be determined by the Corporation's management and would depend on a variety of factors including price, corporate and regulatory requirements, capital availability and other market conditions. Common stock acquired through the share repurchase program would be held as treasury shares and may be used for general corporate purposes, including reissuance in connection with acquisitions, employee stock option exercises or other employee stock plans. The share repurchase program does not have an expiration date and may be limited, terminated or extended at any time without prior notice. During the nine months ended September 30, 2015, the Corporation repurchased no shares of common stock.

The Corporation may redeem shares from employees upon the vesting of the Corporation's stock awards for minimum statutory tax withholding purposes and to cover option exercise costs. The Corporation redeemed 156,963 shares from the vesting of certain awards and exercise of certain stock options, for an aggregate price of approximately \$4.3 million during the nine months ended September 30, 2015. These shares have also been designated by the Corporation as treasury stock.

15

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 8—COMMON STOCK, PREFERRED STOCK, TREASURY STOCK, STOCK-BASED COMPENSATION AND OTHER BENEFITS (Continued)

Stock Option Activity

Stock options were not granted to officers and employees during 2014 or the nine months ended September 30, 2015. The following table summarizes option activity for the periods presented:

| | Number of Shares | Weighted- Average Exercise Price Per Share | Weighted- Average Remaining Term | Aggregate Intrinsic Value (in millions) |
|--|------------------------|--|---|---|
| Outstanding shares at December 31, 2014 | 913,209 | \$ 14.62 | 2.1 years | \$ 5.6 |
| Exercised | (139,133) | 15.43 | | |
| Canceled | (122,268) | 11.74 | | |
| Expired | (303) | 13.42 | | |
| Outstanding shares at September 30, 2015 | 651,505 | \$ 14.30 | 1.55 years | \$ 9.2 |
| Exercisable shares at September 30, 2015 | 651,505 | \$ 14.30 | 1.55 years | \$ 9.2 |

Nonvested Shares

The following table summarizes nonvested share activity for the periods presented:

| | Number of Shares | Weighted- Average Grant Date Fair Value |
|--|---------------------|---|
| Outstanding shares at December 31, 2014 | 942,021 | \$ 18.00 |
| Granted - Restricted Stock Units | 171,619 | 28.87 |
| Granted - Performance Share Units | 155,831 | 26.60 |
| Forfeited | (6,929) | 22.58 |
| Vested | (362,632) | 16.23 |
| Outstanding shares at September 30, 2015 | 899,910 | \$ 22.24 |

The weighted average remaining term and intrinsic value of non-vested shares as of September 30, 2015 was 2.9 years and \$25.6 million, respectively.

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 9—INCOME TAXES

The provision for income taxes is based upon the Corporation's estimate of annual taxable income or loss for each respective accounting period. The following table summarizes our provision for income taxes for the periods presented (dollars in millions):

The provision for income taxes is based upon the Corporation's estimate of annual taxable income or loss for each respective accounting period. The following table summarizes our provision for income taxes for the periods presented (dollars in millions):

| | Three Months | | Nine Months | |
|---|---------------|-------|---------------|--------|
| | Ended | | Ended | |
| | September 30, | | September 30, | |
| | 2014 | 2015 | 2014 | 2015 |
| Provision for income taxes | \$2.2 | \$3.4 | \$2.9 | \$13.5 |
| Total provision as a percentage of pre-tax income | 20.6% | 53.1% | 44.6% | 47.5% |

The increase in our provision for income taxes as a percentage of pre-tax income for the nine months ended September 30, 2015 compared to the comparable 2014 period was due primarily to increases in the amount of pre-tax income as well as certain non-deductible employee compensation costs and discrete items. The provision for income taxes for the nine months ended September 30, 2014 was significantly impacted by the Corporation's \$26.6 million of legal charges. The effective tax rates in 2015 are higher than the federal statutory rate largely as a result of the combined impact of state and local taxes, various non-deductible expenses, and discrete events. The discrete events for the nine months ended September 30, 2015 included a non-deductible \$4.4 million legal charge and \$1.2 million of other items.

The Corporation derives a current federal and state income tax benefit from the impact of deductions associated with the amortization of tax deductible goodwill acquired through business combinations. The tax basis of the Corporation's tax deductible goodwill was approximately \$145.3 million and \$152.6 million at December 31, 2014 and September 30, 2015, respectively. The future tax benefits of the tax-deductible goodwill are included in the Corporation's deferred tax assets.

The Corporation recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets are recovered or liabilities are settled. The Corporation also recognizes as deferred tax assets the future tax benefits from net operating loss carryforwards. As of September 30, 2015, the Corporation has \$20.4 million (\$7.1 million tax benefit) of federal net operating loss carryforwards available related to a 2014 acquisition. The Corporation's ability to utilize these loss carryovers is limited, but the Corporation expects that it will be able to use the recorded amount which takes into account the limitations of the carryforwards. Accordingly, the Corporation has not recorded any valuation allowance for the associated deferred tax asset. The Corporation has state net operating loss carryforwards representing a tax benefit of \$3.6 million, net of valuation allowances. The net operating losses have carryforward periods ranging from 1 to 20 years depending on the taxing jurisdiction.

A valuation allowance is provided for the Corporation's deferred tax assets if it is more likely than not that some portion or all of the net deferred tax assets will not be realized. The Corporation recognized net deferred tax assets totaling \$27.1 million at December 31, 2014 (as adjusted) and \$23.0 million at September 30, 2015, net of state valuation allowances of \$4.1 million as of both periods.

As of December 31, 2014 and September 30, 2015, the Corporation had no reserves recorded for unrecognized tax benefits for U.S. federal and state tax jurisdictions.

The federal statute of limitations remains open for tax years 2012 through 2014. The IRS completed its audit of the Corporation's consolidated U.S. income tax return for the 2011 tax year in February 2014.

State tax jurisdictions generally have statutes of limitation ranging from three to five years. The Corporation is generally no longer subject to state and local income tax examinations by tax authorities for years before 2009. The state income tax impact of federal income tax changes remains subject to examination by various states for a period of up to one year after formal notification of IRS settlement to the states.

17

PHARMERICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

NOTE 10—EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per share (dollars in millions, except per share amounts):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2014 | 2015 | 2014 | 2015 |
| Numerator: | | | | |
| Numerator for basic and diluted earnings per share - net income | \$8.5 | \$3.0 | \$3.6 | \$14.9 |
| Denominator: | | | | |
| Denominator for basic earnings per share - weighted average shares | 30,073,133 | 30,431,845 | 29,944,875 | 30,336,548 |
| Effect of dilutive securities (stock options, restricted stock units and performance share units) | 522,169 | 464,449 | 558,053 | 462,286 |
| Denominator for earnings per diluted share - adjusted weighted average shares | 30,595,302 | 30,896,294 | 30,502,928 | 30,798,834 |
| Basic earnings per share | \$0.28 | \$0.10 | \$0.12 | \$0.49 |
| Earnings per diluted share | \$0.28 | \$0.10 | \$0.12 | \$0.48 |
| Unexercised employee stock options and unvested restricted shares excluded from the effect of dilutive securities above (a) | 465,377 | 197 | 481,844 | 504 |

(a) These unexercised employee stock options, unvested restricted shares and performance shares that have not yet met performance conditions are not included in the computation of diluted earnings per share because to do so would be anti-dilutive for the periods presented.

Stock options and restricted shares and units granted by the Corporation are treated as potential common shares outstanding in computing earnings per diluted share. Performance share units are treated as potential common shares outstanding in computing earnings per diluted share only when the performance conditions are met.

Common shares repurchased by the Corporation reduce the number of basic shares used in the denominator for basic and diluted earnings per share.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect the Corporation's current estimates, expectations and projections about the Corporation's future results, performance, prospects and opportunities. Forward looking statements include, among other things, the information concerning the Corporation's possible future results of operations including revenues, costs of goods sold, and gross margin, business and growth strategies, financing plans, the Corporation's competitive position and the effects of competition, the projected growth of the industries in which we operate, and the Corporation's ability to consummate strategic acquisitions. Forward-looking statements include statements that are not historical facts and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "plan," "may," "should," "will," "would," "project," and similar expressions. These forward-looking statements are based upon information currently available to the Corporation and are subject to a number of risks, uncertainties and other factors that could cause the Corporation's actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Important factors that could cause the Corporation's actual results to differ materially from the results referred to in the forward-looking statements the Corporation makes in this report include:

- the Corporation's access to capital, credit ratings, indebtedness, and ability to raise additional financings and operate under the terms of the Corporation's debt obligations;
- anti-takeover provisions of the Delaware General Corporation Law, which in concert with our certificate of incorporation and our by-laws could delay or deter a change in control;
- the effects of adverse economic trends or intense competition in the markets in which we operate;
- the Corporation's risk of loss of revenues due to a customer or owner of skilled nursing facility entering the institutional pharmacy business;
- the effects of the loss of a large customer and the Corporation's ability to adequately restructure its operations to offset the loss;
- the demand for the Corporation's products and services;
- the risk of retaining existing customers and service contracts and the Corporation's ability to attract new customers for growth of the Corporation's business;
- the effects of renegotiating contract pricing relating to significant customers and suppliers, including the hospital pharmacy business which is substantially dependent on service provided to one customer;
- the impacts of cyber security risks and/or incidents;
- the effects of a failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service;
- the effects of an increase in credit risk, loss or bankruptcy of or default by any significant customer, supplier, or other entity relevant to the Corporation's operations;
- the Corporation's ability to successfully pursue the Corporation's development and acquisition activities and successfully integrate new operations and systems, including the realization of anticipated revenues, economies of scale, cost savings, and productivity gains associated with such operations;
- the Corporation's ability to control costs, particularly labor and employee benefit costs, rising pharmaceutical costs, and regulatory compliance costs;
- the effects of healthcare reform and government regulations, including interpretation of regulations and changes in the nature and enforcement of regulations governing the healthcare and institutional pharmacy services industries including the dispensing of antipsychotic prescriptions;
- changes in the reimbursement rates or methods of payment from Medicare and Medicaid and other third party payers to both us and our customers;
-

the potential impact of state government budget shortfalls and their ability to pay the Corporation and its customers for services provided;

the Corporation's ability, and the ability of the Corporation's customers, to comply with Medicare or Medicaid reimbursement regulations or other applicable laws;

the effects of changes in the interest rate on the Corporation's outstanding floating rate debt instrument and the increases in interest expense, including increases in interest rate terms on any new debt financing;

further consolidation of managed care organizations and other third party payers;

political and economic conditions nationally, regionally, and in the markets in which the Corporation operates;

natural disasters, war, civil unrest, terrorism, fire, floods, tornadoes, earthquakes, hurricanes, epidemic, pandemic, catastrophic event or other matters beyond the Corporation's control;

increases in energy costs, including state and federal taxes, and the impact on the costs of delivery expenses and utility expenses;

elimination of, changes in, or the Corporation's failure to satisfy pharmaceutical manufacturers' rebate programs;

the Corporation's ability to attract and retain key executives, pharmacists, and other healthcare personnel;

the Corporation's risk of loss not covered by insurance;

the outcome of litigation to which the Corporation is a party from time to time, including adverse results in material litigation or governmental inquiries including the possible insufficiency of any accruals established by the Corporation from time to time;

changes in accounting rules and standards, audits, compliance with the Sarbanes-Oxley Act, and regulatory investigations;

changes in market conditions that would result in the impairment of goodwill or other assets of the Corporation;

changes in market conditions in which we operate that would influence the value of the Corporation's stock;

the uncertainty as to the long-term value of the Corporation's common stock;

the Corporation's ability to anticipate a shift in demand for generic drug equivalents and the impact on the financial results including the negative impact on brand drug rebates;

the effect on prescription volumes and the Corporation's net revenues and profitability if the safety risk profiles of drugs increase or if drugs are withdrawn from the market, including as a result of manufacturing issues, or if prescription drugs transition to over-the-counter products;

the effects on the Corporation's results of operations related to interpretations of accounting principles by the SEC staff that may differ from those of management;

- the potential impact of the litigation proceedings with ABDC regarding the Amended PVA;
- the Corporation's ability to comply with the terms of its Memorandum of Agreement with the DEA and the Corporate Integrity Agreement with the OIG;
- the Corporation's ability to collect outstanding receivables;
- changes in tax laws and regulations;
- the effects of changes to critical accounting estimates; and
- other factors, risks and uncertainties referenced in the Corporation's filings with the Commission, including the "Risk Factors" set forth in the Corporation's Annual Report on Form 10-K for the year ended December 31, 2014.

YOU ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON ANY FORWARD-LOOKING STATEMENTS, ALL OF WHICH SPEAK ONLY AS OF THE DATE OF THIS QUARTERLY REPORT. EXCEPT AS REQUIRED BY LAW, WE UNDERTAKE NO OBLIGATION TO PUBLICLY UPDATE OR RELEASE ANY REVISIONS TO THESE FORWARD-LOOKING STATEMENTS TO REFLECT ANY EVENTS OR CIRCUMSTANCES AFTER THE DATE OF THIS QUARTERLY REPORT OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS. ALL SUBSEQUENT WRITTEN AND ORAL FORWARD-LOOKING STATEMENTS ATTRIBUTABLE TO US OR ANY PERSON ACTING ON THE CORPORATION'S BEHALF ARE EXPRESSLY QUALIFIED IN THEIR ENTIRETY BY THE CAUTIONARY STATEMENTS CONTAINED OR REFERRED TO IN THIS SECTION AND IN OUR RISK FACTORS SET FORTH IN PART I, ITEM 1A OF THE CORPORATION'S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2014 AND IN OTHER REPORTS FILED WITH THE SEC BY THE CORPORATION.

20

General

The condensed consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations included in this quarterly report on Form 10-Q as of and for the three and nine months ended September 30, 2015, reflect the financial position, results of operations, and cash flows of the Corporation.

Unless the context otherwise requires, all references to "we," "us," "our," and "Corporation" refer to PharMerica Corporation and its subsidiaries.

Institutional Pharmacy Business

Our core business provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals, and other long-term alternative care settings. We purchase, repackage, and dispense prescription and non-prescription pharmaceuticals in accordance with physician orders and deliver such medication to healthcare facilities for administration to individual patients and residents. Depending on the specific location, we service healthcare facilities typically within a radius of 120 miles or less of our pharmacy locations at least once each day. We provide 24-hour, seven-day per week on-call pharmacist services for emergency dispensing, delivery, and/or consultation with the facility's staff or the resident's attending physician. We also provide various supplemental healthcare services that complement our institutional pharmacy services.

We offer prescription and non-prescription pharmaceuticals to our customers through unit dose or modified unit dose packaging, dispensing, and delivery systems, typically in a 14 to 30 day supply. Unit dose medications are packaged for dispensing in individual doses as compared to bulk packaging used by most retail pharmacies. The customers we serve prefer the unit dose delivery system over the bulk delivery system employed by retail pharmacies because it improves control over the storage and ordering of drugs and reduces errors in drug administration in healthcare facilities. Nursing staff in our customers' facilities administer the pharmaceuticals to individual patients and residents. The Corporation also utilizes an on-site dispensing system, with real time data transfer between the system and the Corporation, which provides timely medication administration in emergency and first dose situations. We also offer clinical pharmacy programs that encompass a wide range of drug therapy and disease management protocols, including protocols for anemia treatment, infectious diseases, wound care, nutritional support, renal dosing, and therapeutic substitution.

Our computerized dispensing and delivery systems are designed to improve efficiency and control over distribution of medications to patients and residents. We provide computerized physician orders and medication administration records for patients or residents on a monthly basis as requested. Data from these records are formulated into monthly management reports on patient and resident care and quality assurance. This system improves efficiencies in nursing time, reduces drug waste, and helps to improve patient outcomes.

Hospital Pharmacy Management Services

We also provide hospital pharmacy management services. These services generally entail the overall management of the hospital pharmacy operations, including the ordering, receipt, storage, and dispensing of pharmaceuticals to the hospital's patients pursuant to the clinical guidelines established by the hospital. We offer the hospitals a wide range of regulatory and financial management services, including inventory control, budgetary analysis, staffing optimization, and assistance with obtaining and maintaining applicable regulatory licenses, certifications, and accreditations. We work with the hospitals to develop and implement pharmacy policies and procedures, including drug formulary development and utilization management. We also offer clinical pharmacy programs that encompass a wide range of drug therapy and disease management protocols, including protocols for anemia treatment, infectious diseases, wound care, nutritional support, renal dosing, and therapeutic substitution. The hospital pharmacy management services business is comprised of a few customers, of which, our largest service is to the majority of the Kindred Healthcare ("Kindred") hospitals.

Consultant Pharmacist Services

Federal and state regulations mandate that long-term care facilities, in addition to providing a source of pharmaceuticals, retain consultant pharmacist services to monitor and report on prescription drug therapy in order to maintain and improve the quality of resident care. On September 30, 2008, the United States Department of Health and Human Services Office of Inspector General ("OIG") published OIG Supplemental Compliance Program Guidance for Nursing Homes. With quality of care being the first risk area identified, the supplemental guidance is part of a series of recent government efforts focused on improving quality of care at skilled nursing and long-term care facilities. The guidance contains compliance recommendations and an expanded discussion of risk areas. The guidance stressed that facilities must provide pharmaceutical services to meet the needs of each resident and should be mindful of potential quality of care problems when implementing policies and procedures on proper medication management. It further stated that facilities can reduce risk by educating staff on medication management and improper pharmacy kickbacks for consultant pharmacists and that facilities should review the total compensation paid to consultant pharmacists to ensure it is not structured in a way that reflects the volume or value of particular drugs prescribed or administered to residents.

We provide consultant pharmacist services to approximately 67% of our patients serviced. The services offered by our consultant pharmacists include:

- Monthly reviews of each resident's drug regimen to assess the appropriateness and efficiency of drug therapies, including the review of medical records, monitoring drug interactions with other drugs or food, monitoring laboratory test results, and recommending alternative therapies;
- Participation on quality assurance and other committees of our customers, as required or requested by such customers;
- Monitoring and reporting on facility-wide drug utilization;
- Development and maintenance of pharmaceutical policy and procedure manuals; and
- Assistance with federal and state regulatory compliance pertaining to resident care.

Medical Records

The Corporation provides medical records services, which includes the completion and maintenance of medical record information for patients in the Corporation's customers' facilities. The medical records services include:

- Real-time access to medication and treatment administration records, physician order sheets and psychotropic drug monitoring sheets;
- Online ordering to save time and resources;
- A customized database with the medication profiles of each resident's medication safety, efficiency and regulatory compliance;
- Web-based individual patient records detailing each prescribed medicine; and
- Electronic medical records to improve information to make it more legible and instantaneous.

Specialty Infusion Services

The Corporation provides specialty infusion services focused on providing complex pharmaceutical products and clinical services to patients in client facilities, hospice, and outside of hospital or nursing home settings. We offer high-touch clinical services to patients with acute or chronic conditions. The delivery of specialty infusion therapy requires comprehensive planning and monitoring which is provided through our registered nursing staff. Our nursing staff performs an initial patient assessment, provides therapy specific training and education, administers therapy and monitors for potential side effects. We also provide extensive clinical monitoring and patient follow-up to ensure patient therapy adherence and proactively manage patients' conditions. An in-network strategy facilitates easier decision-making for referral sources and provides us with the ability to pre-authorize patients, auto adjudicate, and bill electronically, enabling faster prescription turnaround.

Specialty Oncology Pharmacy

We provide dispensing of oncology drugs, care management and other related services to patients, oncology practices, and hospitals. These services encompass clinical coordination and review, compliance to appropriate oncology protocols, patient assistance with outside funding, and timely delivery of medication. We coordinate the administration of medications to the physician's office or directly to the patient at the appropriate point of treatment. We work directly with the payers to bill insurance companies for the medication provided, ensuring all prior authorizations and approvals are obtained. These services offer physicians an alternative to the traditional buy-and-bill distribution model, allowing them to outsource drug procurement, inventory management, and prescription administration.

Suppliers/Inventory

We obtain pharmaceutical and other products from Cardinal Health ("Cardinal") and other contracts negotiated directly with pharmaceutical manufacturers for discounted prices. The Corporation entered into a Prime Vendor Agreement with Cardinal effective April 1, 2015. The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable.

We seek to maintain an on-site inventory of pharmaceuticals and supplies to ensure prompt delivery to our customers. Cardinal maintains local distribution facilities in most major geographic markets in which we operate. In addition, beginning in the fourth quarter of 2013, we began supplying many of our pharmacies with select products from a distribution center operated by a third-party logistics company.

Brand to Generic Conversions

The following table summarizes the material brand-to-generic conversions expected to occur in 2015 through 2018:

| 2015 | 2016 | 2017 | 2018 |
|--------------|------------------|--------------|--------------|
| Patanol (Q4) | Gleevec (Q1) | Azilect (Q1) | Nasonex (Q2) |
| Renagel (Q4) | Nuedexta (Q1) | Vytorin (Q2) | |
| Renvela(Q4) | Combivent (Q2) | | |
| | Crestor (Q2) | | |
| | Cubicin (Q2) | | |
| | Tamiflu (Q3) | | |
| | Kaletra (Q4) | | |
| | Seroquel XR (Q4) | | |
| | Zetia (Q4) | | |

(Number in parentheses refers to the expected quarter of conversion)

When a branded drug shifts to a generic, initial pricing of the generic drug in the market will vary depending on the number of manufacturers launching their generic version of the drug. Historically a shift from brand-to-generic decreased our revenue and improved our gross margin from sales of these classes of drugs during the initial time period a brand drug has a generic alternative. However, recent experience has indicated that the third-party payers may reduce their reimbursements to the Corporation faster than previously experienced. In addition, the number of generic manufacturers entering the market impacts the overall cost and reimbursement of generic drugs. This acceleration in the reimbursement reduction and the number of generic manufacturers have resulted in margin compression much earlier than we have historically experienced. Due to the unique nature of the brand-to-generic conversion, management cannot estimate the future financial impact of the brand-to-generic conversions on the Corporation's results of operations.

Supplier and Manufacturer Rebates

We currently receive rebates from certain manufacturers and distributors of pharmaceutical products for achieving targets of market share or purchase volumes. Rebates are designed to prefer, protect, or maintain a manufacturer's products that are dispensed by the pharmacy under its formulary. Rebates for brand name products are generally based upon achieving a defined market share tier within a therapeutic class and can be based on either purchasing volumes or actual prescriptions dispensed. Rebates for generic products are more likely to be based on achieving purchasing volume requirements.

2010 Health Care Reform Legislation

The Patient Protection and Affordable Care Act and the reconciliation law known as Health Care and Education Affordability Reconciliation Act (combined we refer to both Acts as the "2010 Health Care Reform Legislation") were enacted in March 2010. State participation in the expansion of Medicaid under the 2010 Health Care Reform Legislation is voluntary. Three key provisions of the 2010 Health Care Reform Legislation that are relevant to the Corporation are: (i) the gradual modification to the calculation of the Federal Upper Limit ("FUL") for drug prices and the definition of Average Manufacturer's Price ("AMP"), (ii) the closure, over time, of the Medicare Part D coverage gap, which is otherwise known as the "Donut Hole," and (iii) short cycle dispensing. Regulations under the 2010 Health Care Reform Legislation are expected to continue being drafted, released, and finalized throughout the next several years.

FUL and AMP Changes

The reimbursement rates for pharmacy services under Medicaid are determined on a state-by-state basis subject to review by Centers for Medicare and Medicaid Services ("CMS") and applicable federal law. Although Medicaid programs vary from state to state, they generally provide for the payment of certain pharmacy services, up to the established limits, at rates determined in accordance with each state's regulations. Federal regulations and the regulations of certain states establish "upper limits" for reimbursement of certain prescription drugs under Medicaid (these upper limits being the "FUL").

The 2010 Health Care Reform Legislation amended the Deficit Reduction Act of 2005 (the "DRA") to change the definition of the FUL by requiring the calculation of the FUL as no less than 175% of the weighted average, based on utilization, of the most recently reported monthly AMP for pharmaceutically and therapeutically equivalent multi-source drugs available through retail community pharmacies nationally.

In addition, the definition of AMP changed to reflect net sales only to drug wholesalers that distribute to retail community pharmacies and to retail community pharmacies that directly purchase from drug manufacturers. Further, the 2010 Health Care Reform Legislation continues the current statutory exclusion of prompt pay discounts offered to wholesalers and adds three other exclusions to the AMP definition: (i) bona fide services fees; (ii) reimbursement for unsalable returned goods (recalled, expired, damaged, etc.); and (iii) payments from and rebates/discounts to certain entities not conducting business as a wholesaler or retail community pharmacy. In addition to reporting monthly, the manufacturers are required to report the total number of units used to calculate each monthly AMP. CMS will use this information when it establishes FULs as a result of the new volume-weighted requirements pursuant to the 2010 Health Care Reform Legislation.

In September 2011, CMS issued the first draft FUL reimbursement files for multiple source drugs, including the draft methodology used to calculate the FULs in accordance with the 2010 Health Care Reform Legislation. CMS continues to release this monthly data and a three-month rolling average and is expected to do so going forward. CMS has not posted monthly AMPs for individual drugs, but only posted the weighted average of monthly AMPs in a FUL group and the calculation methodology.

CMS has stated that AMP-based FULs will be published at or about the same time that CMS publishes the Medicaid Covered Outpatient Drug final rule. On August 4, 2015, the Office of the Management and Budget (the "OMB") received the Medicaid Covered Outpatient Drug final rule for final review. The OMB website stated that it expected final action on this rule in August 2015; however, final action has not yet been taken.

CMS will continue to post draft monthly FULs. The Corporation will continue to analyze the draft monthly FULs, including the relationship of those FULs to the National Average Drug Acquisition pricing.

Part D Coverage Gap

Starting on January 1, 2011, the Medicare Coverage Gap Discount Program (the "Program") requires drug manufacturers to provide a 50% discount on the negotiated ingredient cost to certain Medicare Part D beneficiaries for certain drugs and biologics purchased during the coverage gap (this is exclusive of the pharmacy dispensing fee). In addition, the 2010 Health Care Reform Legislation requires Medicare to close or eliminate the coverage gap entirely by fiscal year 2020 by gradually reducing the coinsurance percentage for both drugs covered and not covered by the Program for each applicable beneficiary.

At this time, the Corporation is unable to fully evaluate the impact of the changes to the coverage gap to its business.

Short Cycle Dispensing and Dispensing Fees

Pursuant to the 2010 Health Care Reform Legislation, Prescription Drug Plans ("PDPs") are required, under Medicare Part D and Medicare Advantage prescription drug plans ("Medicare Advantage" or "MAPDs") to utilize specific, uniform dispensing techniques, such as weekly, daily, or automated dose dispensing, when dispensing covered Medicare Part D drugs to beneficiaries who reside in a long-term care facility to reduce waste associated with 30 to 90 day prescriptions for such beneficiaries. Pursuant to CMS issued regulation, beginning January 1, 2013, pharmacies dispensing to long-term care facilities must dispense no more than 14-day supplies of brand-name oral solid medications covered by Medicare Part D. The Corporation fully implemented short cycle dispensing on January 1, 2013. The impact of short cycle dispensing has not had a material adverse impact on the Corporation's results of operations.

In a February 12, 2015 Final Rule entitled "Medicare Program: Contract Year 2016 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs", CMS finalized a regulation, effective January 1, 2016, prohibiting financial arrangements that penalize more efficient long-term care dispensing techniques (e.g., dispensing a three day supply over a 14-day supply) through pro-rated dispensing fees based on a day's supply or quantity dispensed. CMS also finalized a requirement that, effective January 1, 2016, any differences in payment methodologies among long-term care pharmacies incentivize more efficient dispensing techniques. The Corporation is unable to evaluate the full impact of these changes on its business at this time.

Medicare Part D Changes

In a May 23, 2014 Final Rule entitled "Medicare Program: Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs," CMS finalized a requirement that applicable January 1, 2016 and enforceable June 1, 2016, certain prescribers of Part D covered drugs must be enrolled as Medicare providers (or be granted a valid opt-out affidavit on file with a Part A or Part B Medicare Administrative Contractor) in order for a claim to be covered under Medicare Part D. CMS also finalized several specific requirements to reduce prescriber fraud, waste, and abuse. The Corporation is unable to evaluate the full impact of these changes on its business at this time.

CIA and DEA MOA

In May 2015, the Corporation entered into a five-year corporate integrity agreement ("CIA") with the OIG and a Memorandum of Agreement ("MOA") with the Drug Enforcement Agency ("DEA") concurrent with the execution of settlement agreements with the OIG and the DEA settling alleged Controlled Substance Act ("CSA") violations and associated False Claims Act allegations.

The CIA requires the Corporation, among other things to: (i) create procedures designed to ensure it complies with the CSA and related regulations; (ii) retain an independent review organization to review the Corporation's compliance with the terms of the CIA and report to the OIG regarding that compliance; and (iii) provide training for certain Corporation employees as to the Corporation's requirements under the CSA. If the Corporation fails to comply with the terms of the CIA, it may be required to pay certain monetary penalties. Furthermore, if the Corporation commits a material breach of the CIA, the OIG may exclude the Corporation from participating in federal healthcare programs. Any such exclusion would result in the revocation or termination of contracts and/or licenses and potentially have a material adverse effect on our financial condition, results of operations and business prospects.

The MOA provides for an independent obligation for the Corporation to comply with all requirements of the CSA, specifically relating to the dispensing of Scheduled prescription drugs. If the Corporation fails to comply with the terms of the MOA, the DEA may suspend a Corporation's pharmacy's DEA Certificate of Registration and begin an administrative hearing process pursuant to 21 U.S.C. § 824. Any such suspension would prohibit the Corporation's pharmacy from dispensing Scheduled prescription drugs and would lead to the revocation or termination of contracts and/or licenses and potentially have a materially adverse effect on our financial condition, results of operation and business prospects.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. Management considers an accounting estimate to be critical if:

- It requires assumptions to be made that were uncertain at the time the estimate was made; and
- Changes in the estimate or different estimates could have a material impact on our condensed consolidated results of operations or financial condition.

The critical accounting estimates discussed below are not intended to be a comprehensive list of all of the Corporation's accounting policies that require estimates. Management believes that of the significant accounting policies, discussed in Note 1 of the condensed consolidated financial statements included in this report, the estimates discussed below involve a higher degree of judgment and complexity. Management believes the current assumptions and other considerations used to estimate amounts reflected in the condensed consolidated financial statements are appropriate. However, if actual experience differs from the assumptions and other considerations used in estimating amounts reflected in the condensed consolidated financial statements, the resulting changes could have a material adverse effect on the condensed consolidated results of operations and financial condition of the Corporation.

Allowance for doubtful accounts and provision for doubtful accounts

Accounts receivable primarily consist of amounts due from PDP's under Medicaid Part D, long-term care institutions, respective state Medicaid programs, private payers and third party insurance companies. Our ability to collect outstanding receivables is critical to our results of operations and cash flows. We establish an allowance for doubtful accounts to reduce the carrying value of our receivables to their estimated net realizable value. In addition, certain drugs dispensed are subject to being returned and the responsible paying parties are due a credit for such returns.

Our quarterly provision for doubtful accounts included in our condensed consolidated statements of operations is as follows (dollars in millions):

| | 2014 | | 2015 | |
|----------------|--------|---------------|----------------|---------------|
| | Amount | % of Revenues | Amount | % of Revenues |
| First Quarter | \$5.6 | 1.2 | First Quarter | \$5.0 1.0 |
| Second Quarter | 5.7 | 1.3 | Second Quarter | 3.0 0.6 |
| Third Quarter | 5.3 | 1.1 | Third Quarter | 1.5 0.3 |
| Fourth Quarter | 6.6 | 1.3 | | |

The following table shows our pharmacy revenue days outstanding reflected in our net accounts receivable as of the quarters indicated:

| | 2014 | 2015 |
|----------------|------|------|
| First Quarter | 37.7 | 34.0 |
| Second Quarter | 37.0 | 35.4 |
| Third Quarter | 36.7 | 35.5 |
| Fourth Quarter | 34.9 | |

The following table shows our summarized aging categories by quarter:

| 2014 | 2015 |
|------|------|
|------|------|

Edgar Filing: PharMerica CORP - Form 10-Q

| | First | Second | Third | Fourth | First | Second | Third |
|----------------|-------|--------|-------|--------|-------|--------|-------|
| 0 to 60 days | 56.7% | 53.9 % | 57.3% | 58.8 % | 61.4% | 60.0 % | 58.9% |
| 61 to 120 days | 17.7 | 17.3 | 16.9 | 17.2 | 15.8 | 15.7 | 15.2 |
| Over 120 days | 25.6 | 28.8 | 25.8 | 24.0 | 22.8 | 24.3 | 25.9 |

The following table shows our allowance for doubtful accounts as a percent of gross accounts receivable (dollars in millions):

| | 2014 | | | | 2015 | | |
|----------------|--------------------------------|------------|--------------------------------------|-----------------|--------------------------------|------------|--------------------------------------|
| | Gross Accounts Allowable | Receivable | % of Gross Accounts Receivable | | Gross Accounts Allowable | Receivable | % of Gross Accounts Receivable |
| First Quarter | \$57.7 | \$ 242.2 | 23.8 | % First Quarter | \$59.7 | \$ 259.2 | 23.0 |
| Second Quarter | 60.3 | 246.5 | 24.5 | Second Quarter | 58.8 | 257.9 | 22.8 |
| Third Quarter | 57.4 | 272.4 | 21.1 | Third Quarter | 57.7 | 253.5 | 22.8 |
| Fourth Quarter | 58.1 | 253.5 | 22.9 | | | | |

We recognize revenues at the time services are provided or products are delivered. A significant portion of our revenues are billed to PDPs under Medicare Part D, state Medicaid programs, long-term care institutions, third party insurance companies, and private payers. Some claims are electronically adjudicated through online processing at the point the prescriptions are dispensed such that our operating system is automatically updated with the actual amounts to be reimbursed. As a result, our revenues and the associated receivables are based upon the actual reimbursements to be received. For claims that are adjudicated on-line and are rejected or otherwise denied upon submission, the Corporation provides contractual allowances based upon historical trends, contractual reimbursement terms and other factors which may impact ultimate reimbursement. Amounts are adjusted to actual reimbursed amounts based upon cash receipts.

Edgar Filing: PharMerica CORP - Form 10-Q

A summary of revenues by payer type follows (dollars in millions):

| | Three Months Ended September 30, | | | | | |
|------------------------------------|----------------------------------|---------------|-----------|---------------|--------|---|
| | 2014 | | 2015 | | | |
| | Amount | % of Revenues | Amount | % of Revenues | Amount | % |
| Medicare Part D | \$214.6 | 45.6 | % \$234.6 | 47.0 | % | |
| Institutional healthcare providers | 110.4 | 23.5 | 114.5 | 23.0 | | |
| Medicaid | 39.5 | 8.4 | 34.3 | 6.9 | | |
| Private and other | 19.5 | 4.1 | 19.9 | 4.0 | | |
| Insured | 64.8 | 13.8 | 74.2 | 14.9 | | |
| Medicare | 5.9 | 1.3 | 5.7 | 1.1 | | |
| Hospital management fees | 15.5 | 3.3 | 15.6 | 3.1 | | |
| Total | \$470.2 | 100.0 | % \$498.8 | 100.0 | % | |

| | Nine Months Ended September 30, | | | | | |
|------------------------------------|---------------------------------|---------------|-------------|---------------|--------|---|
| | 2014 | | 2015 | | | |
| | Amount | % of Revenues | Amount | % of Revenues | Amount | % |
| Medicare Part D | \$618.2 | 45.1 | % \$703.2 | 46.6 | % | |
| Institutional healthcare providers | 337.3 | 24.6 | 354.1 | 23.5 | | |
| Medicaid | 122.9 | 9.0 | 110.8 | 7.4 | | |
| Private and other | 59.0 | 4.3 | 61.6 | 4.0 | | |
| Insured | 173.1 | 12.6 | 215.0 | 14.3 | | |
| Medicare | 16.3 | 1.2 | 16.3 | 1.1 | | |
| Hospital management fees | 44.2 | 3.2 | 46.8 | 3.1 | | |
| Total | \$1,371.0 | 100.0 | % \$1,507.8 | 100.0 | % | |

Inventory and cost of drugs dispensed

We have inventory located at each of our institutional pharmacy, specialty infusion, and specialty oncology locations as well as our drug distribution center. Our inventory is valued at the lower of first-in, first-out cost or market. The inventory consists of prescription drugs, over the counter products and intravenous solutions. Our inventory relating to controlled substances is maintained on a manually prepared perpetual system to the extent required by the Drug Enforcement Agency and state board of pharmacies. All other inventory is maintained on a periodic system, through the performance of, at a minimum, quarterly physical inventory at the end of each quarter. All inventory counts are reconciled to the balance sheet account and differences are adjusted through cost of goods sold. In addition, we record an amount of potential returns of prescription drugs based on historical rates of returns and record an estimate for rebates associated with inventory remaining at the end of each period.

As of December 31, 2014 and September 30, 2015, our inventories were \$135.5 million and \$117.5 million, respectively.

The inventory days on hand were as follows for the periods presented:

| | 2014 | 2015 |
|----------------|------|------|
| First Quarter | 26.0 | 26.1 |
| Second Quarter | 35.1 | 29.6 |

Edgar Filing: PharMerica CORP - Form 10-Q

| | | |
|----------------|------|------|
| Third Quarter | 31.7 | 25.7 |
| Fourth Quarter | 29.1 | |

Goodwill and other intangible assets

Goodwill represents the excess of the purchase price over the fair value of the net assets of acquired companies. Our intangible assets are comprised primarily of trade names, customer relationship assets, and non-compete agreements.

Our goodwill as of December 31, 2014 (as adjusted) and September 30, 2015 was \$323.6 million and \$341.8 million, respectively.

The Corporation's policy is to perform a quantitative assessment of its institutional pharmacy and specialty infusion reporting units to determine whether it is more likely than not (defined as having a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount. The Corporation performed a quantitative assessment as of December 31, 2014. The institutional pharmacy and specialty infusion reporting unit's fair value as calculated for the analysis were approximately 48.2% and 13.1%, respectively, greater than book value at December 31, 2014. As a result of the excess on the specialty infusion unit not being significant, the Corporation continues to closely monitor the results of the specialty infusion reporting unit. The specialty infusion reporting unit had goodwill with a carrying value of \$57.7 million at December 31, 2014. The Corporation also performed a qualitative assessment of its specialty oncology reporting unit as of December 31, 2014 and did not find it necessary to perform the first step of the two-step impairment test based on that analysis.

There were no impairment triggering events during the nine months ended September 30, 2015.

Accounting for income taxes

We assess the likelihood that deferred tax assets will be realized from future taxable income. A valuation allowance is provided for deferred tax assets if it is more-likely-than-not that some portion or all of the net deferred tax assets will not be realized. Our net deferred tax asset balances as of December 31, 2014 and September 30, 2015 were \$27.1 million and \$23.0 million, respectively. Our valuation allowances for state deferred tax assets in our condensed consolidated balance sheets as of December 31, 2014 and September 30, 2015 were \$4.1 million.

Definitions

Listed below are definitions of terms used by the Corporation in managing the business. The definitions are necessary to the understanding of the Management's Discussion and Analysis section of this document.

Gross profit per prescription dispensed: Represents the gross profit divided by the total prescriptions dispensed.

Gross profit margin: Represents the gross profit per prescription dispensed divided by the revenue per prescription dispensed.

Prescriptions dispensed: Represents a prescription filled for an individual patient. A prescription will usually be for a 14 or 30 day period and will include only one drug type.

Revenue per prescription dispensed: Represents the revenue divided by the total prescriptions dispensed.

27

Results of Operations

The following table presents selected consolidated comparative results of operations and statistical information for the periods presented (dollars in millions, except per prescription and per patient amounts, and prescriptions in thousands):

| | Three Months Ended September 30, | | | | | Nine Months Ended September 30, | | | | | | |
|-----------------------|----------------------------------|------------------------|-----------|--------|---------|---------------------------------|------------------------|------------------|---------|------|-----------|------------------|
| | 2014 | Increase (Decrease) | | | 2015 | 2014 | Increase (Decrease) | | | 2015 | | |
| | Amount | % of Revenues | | % | Amount | % of Revenues | Amount | % of Revenues | | % | Amount | % of Revenues |
| Revenues | \$470.2 | 100.0 | \$ 28.6 | 6.1 | \$498.8 | 100.0 | \$1,371.0 | 100.0 | \$136.8 | 10.0 | \$1,507.8 | 100.0 |
| Cost of goods sold | 387.2 | 82.3 | 33.0 | 8.5 | 420.2 | 84.2 | 1,126.1 | 82.1 | 133.3 | 11.8 | 1,259.4 | 83.5 |
| Gross profit | \$83.0 | 17.7 | \$ (4.4) | (5.3) | \$78.6 | 15.8 | \$244.9 | 17.9 | \$3.5 | 1.4 | \$248.4 | 16.5 |

Pharmacy (in whole numbers except where indicated)

| Financial data | | | | | | | | | | | | |
|---|---------|--------|-----------|---------|---------|---------|--------|--------|--------|---------|---|--|
| Prescriptions dispensed (in thousands) | | | | | | | | | | | | |
| | 2014 | Change | | | 2015 | 2014 | Change | | | 2015 | | |
| | Amount | % | | % | Amount | Amount | % | | % | Amount | % | |
| Prescriptions dispensed | 8,492 | | (284) | (3.3) | 8,208 | 25,511 | | 202 | 0.8 | 25,713 | | |
| Revenue per prescription dispensed | \$55.37 | | \$ 5.40 | 9.8 | \$60.77 | \$53.74 | | \$4.90 | 9.1 | \$58.64 | | |
| Gross profit per prescription dispensed | \$9.77 | | \$ (0.19) | (1.9) | \$9.58 | \$9.60 | | \$0.06 | 6.3 | \$9.66 | | |
| Gross profit margin | 17.7 % | | (1.9)% | (10.7)% | 15.8 % | 17.9 % | | (1.4) | (7.8)% | 16.5 % | | |
| Generic dispensing rate | 85.1 % | | 1.4 % | 1.6 % | 86.5 % | 84.9 % | | 1.0 % | 1.2 % | 85.9 % | | |

Revenues

Revenues increased \$28.6 million for the three months ended September 30, 2015 compared to the three months ended September 30, 2014 which was driven by recent acquisitions, growth in the Corporation's specialty pharmacy businesses, and branded drug inflation. The increase of \$28.6 million is comprised of a favorable rate variance of approximately \$44.3 million or \$5.40 increase per prescription dispensed, partially offset by an unfavorable volume variance of approximately \$15.7 million or 284,000 fewer prescriptions dispensed. The revenue per prescription dispensed increase was due to the increased volume in the Corporation's specialty pharmacy businesses, which carries higher revenue per script and branded drug inflation.

Revenues increased \$136.8 million for the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014 which was driven by recent acquisitions, growth in the Corporation's specialty pharmacy businesses, and branded drug inflation. The increase of \$136.8 million is comprised of a favorable rate variance of approximately \$126.0 million or \$4.90 increase per prescription dispensed, along with a favorable volume variance of

approximately \$10.8 million or 202,000 more prescriptions dispensed. The revenue per prescription dispensed increase was due to the increased volume in the Corporation's specialty pharmacy businesses, which carries higher revenue per script and branded drug inflation.

Gross Profit

Gross profit for the three months ended September 30, 2015 was \$78.6 million or \$9.58 per prescription dispensed compared to \$83.0 million or \$9.77 per prescription dispensed for the three months ended September 30, 2014. The decrease in gross profit was primarily driven by lower volumes resulting from an improvement in the Corporation's client mix and higher drug costs under the Corporation's prime vendor agreement.

Gross profit margin for the three months ended September 30, 2015 was 15.8% compared to 17.7% for the three months ended September 30, 2014. The gross profit margin was adversely impacted by the increased volume in the Corporation's specialty pharmacy businesses, which carry lower profit margins as well as volume decreases in the long-term care pharmacy business and higher drug costs under the Corporation's prime vendor agreement.

Gross profit for the nine months ended September 30, 2015 was \$248.4 million or \$9.66 per prescription dispensed compared to \$244.9 million or \$9.60 per prescription dispensed for the nine months ended September 30, 2014. The increase in gross profit was driven by 2014 acquisitions, growth in the Corporation's specialty pharmacy businesses, and branded drug inflation. The increase in gross profit was partially offset by volume decreases in the long-term care pharmacy business and higher drug costs under the Corporation's prime vendor agreement.

Gross profit margin for the nine months ended September 30, 2015 was 16.5% compared to 17.9% for the nine months ended September 30, 2014. The gross profit margin was adversely impacted by the increased volume in the Corporation's specialty pharmacy businesses, which carry lower profit margins as well as volume decreases in the long-term care pharmacy business and higher drug costs under the Corporation's prime vendor agreement.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were \$52.7 million, or 10.6% of revenues, for the three months ended September 30, 2015 compared to \$56.0 million, or 11.9% of revenues, for the three months ended September 30, 2014. The decrease of \$3.3 million was due to cost improvements and a reduction in bad debt expense as the Corporation improved its client mix.

Selling, general and administrative expenses were \$167.1 million, or 11.1% of revenues, for the nine months ended September 30, 2015 compared to \$171.1 million, or 12.5% of revenues, for the nine months ended September 30, 2014. The decrease of \$4.0 million was due to cost improvements and a reduction in bad debt expense as the Corporation improved its client mix.

Depreciation and Amortization

Depreciation expense was \$5.7 million for the three months ended September 30, 2015 as compared to \$4.9 million for the three months ended September 30, 2014 and \$17.2 million for the nine months ended September 30, 2015 as compared to \$14.5 million for the nine months ended September 30, 2014. Depreciation expense increased \$0.8 million for the three months and \$2.7 million for the nine months, due to depreciation expense recognized on the assets acquired through the 2014 Acquisitions as well as additions to fixed assets.

Amortization expense was \$7.0 million for the three months ended September 30, 2015 compared to \$4.9 million for the three months ended September 30, 2014 and \$20.6 million for the nine months ended September 30, 2015 as compared to \$13.6 million for the nine months ended September 30, 2014. The increase of \$2.1 million for the three months and \$7.0 million for the nine months, was due primarily to the amortization expense recognized on intangibles acquired through the 2014 and 2015 acquisitions.

Settlement, Litigation and Other Related Charges

Settlement, litigation and other related charges were \$2.1 million for the three months ended September 30, 2015 compared to \$1.1 million for the three months ended September 30, 2014 and were \$11.3 million for the nine months ended September 30, 2015 as compared to \$28.9 million for the nine months ended September 30, 2014. These costs relate to the Corporation's defense and settlement of certain governmental investigations and other litigation.

Restructuring and Impairment Charges

Restructuring and impairment charges were \$0.2 million for the three months ended September 30, 2015 compared to \$0.1 million for the three months ended September 30, 2014 and were \$0.3 million for the nine months ended September 30, 2015 compared to \$3.2 million for the nine months ended September 30, 2014. These costs are part of the Corporation's initiative to realign the organization in connection with the loss of two significant customers, which were primarily recognized in 2014, along with the specialty infusion restructuring and centralization initiative in 2015.

Merger, Acquisition, Integration Costs and Other Charges

Merger, acquisition, integration costs and other charges were \$8.0 million for the three months ended September 30, 2015 compared to \$3.8 million for the three months ended September 30, 2014 and were \$15.2 million for the nine months ended September 30, 2015 compared to \$10.3 million for the nine months ended September 30, 2014. The increase was related to costs associated with the 2014 and 2015 acquisitions.

Interest Expense

Interest expense was \$2.1 million for the three months ended September 30, 2015 and 2014 and was \$5.4 for the nine months ended September 30, 2015 compared to \$6.9 million for the nine months ended September 30, 2014. The decrease was primarily due to lower interest rates as a result of the new credit agreement signed in 2014, along with lower amortization of deferred financing costs.

Tax Provision

The effective tax rate for the nine months ended September 30, 2015 was 47.5%, comprised of the 35.0% federal statutory rate and 2.2% for the state rate, and 10.3% for discrete events. The discrete events included a non-deductible \$4.4 million legal charge and \$1.2 million of other items. Excluding the impact of the discrete events, the provision for income taxes as a percentage of pre-tax income would have been 37.2%. The effective tax rate excluding discrete events for the nine months ended September 30, 2014 was 37.0%. The increase in the effective tax rate excluding the

impact of the discrete events between the two periods was primarily the result of an increase in certain non-deductible employee compensation costs.

29

Liquidity and Capital Resources

Cash Flows - The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented (dollars in millions):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|--|--------|---------------------------------------|--------|
| | 2014 | 2015 | 2014 | 2015 |
| Net cash provided by (used in) operating activities | \$19.7 | \$37.5 | \$(2.4) | \$59.6 |
| Net cash used in investing activities | (113.4) | (6.8) | (143.3) | (38.3) |
| Net cash provided by (used in) financing activities | 89.7 | (12.0) | 128.6 | (14.6) |
| Net change in cash and cash equivalents | (4.0) | 18.7 | (17.1) | 6.7 |
| Cash and cash equivalents at beginning of period | 11.1 | 21.3 | 24.2 | 33.3 |
| Cash and cash equivalents at end of period | \$7.1 | \$40.0 | \$7.1 | \$40.0 |

Operating Activities – Cash provided by operating activities aggregated \$37.5 million for the three months ended September 30, 2015 and \$59.6 million for the nine months ended September 30, 2015 compared to \$19.7 million for the three months ended September 30, 2014 and cash used in operating activities of \$2.4 million for the nine months ended September 30, 2014. The increase in cash from operating activities is due primarily to the \$48.8 million in ABDC drug purchase payments withheld, the Corporation's inventory purchasing strategy and new prime vendor agreement, and an increase in net income in the nine months ended September 30, 2015, which were partially offset by an increase in ABDC rebates receivable.

Investing Activities – Cash used in investing activities aggregated \$6.8 million and \$38.3 million for the three and nine months ended September 30, 2015, respectively, compared to \$113.4 million and \$143.3 million for the three and nine months ended September 30, 2014, respectively. The decrease is due to the acquisitions completed by the Corporation in the third quarter of 2014.

Financing Activities – Cash used in financing activities aggregated \$12.0 million for the three months ended September 30, 2015 and \$14.6 million for the nine months ended September 30, 2015 compared to cash provided by financing activities of \$89.7 million and \$128.6 million for the three and nine months ended September 30, 2014, respectively. The decrease in cash provided by financing activities is due primarily to borrowings on the revolving credit facility to fund 2014 Acquisitions, along with term and revolving credit facility payments in the third quarter of 2015.

Credit Agreement

On September 17, 2014, the Corporation entered into a Credit Agreement by and among the Corporation, the lenders named therein, Bank of America, N.A., as administrative agent, JP Morgan Chase Bank N.A., as syndication agent, and U.S. Bank, National Association, Citibank, N.A., MUFG Union Bank, N.A., BBVA Compass Bank and SunTrust Bank as co-documentation agents (the "Credit Agreement"). The Credit Agreement consists of a \$225.0 million term loan facility and a \$310.0 million revolving credit facility. The terms and conditions of the Credit Agreement are customary to facilities of this nature. Unless terminated earlier, the Credit Agreement will mature on September 17, 2019, and the principal amount outstanding thereunder, together with all accrued unpaid interest and other amounts owed thereunder, if any, will be payable in full on such date.

The Credit Agreement requires term loan principal payments by the Corporation in an amount of \$2.8 million each quarter beginning September 2015 through September 2019. The final principal repayment installment of term loans shall be repaid on the term maturity date, September 17, 2019. In addition, the term loan is subject to certain

prepayment obligations relating to certain asset sales, certain casualty losses and the incurrence of certain indebtedness.

The Corporation had a total of \$222.2 million outstanding of term debt under the Credit Agreement and \$115.0 million outstanding under the revolving portion of the Credit Agreement as of September 30, 2015. The Credit Agreement provides for the issuance of letters of credit which, when issued, constitute usage and reduce availability on the revolving portion of the Credit Agreement. The amount of letters of credit outstanding as of September 30, 2015 was \$3.0 million. After giving effect to the letters of credit and amounts outstanding under the revolving credit agreement, total availability under the revolving credit facility was \$192.0 million as of September 30, 2015.

The Corporation was compliant with all debt covenant requirements at September 30, 2015.

Drug Wholesaler Agreement

We obtain pharmaceutical and other products from Cardinal pursuant to a Prime Vendor Agreement with Cardinal effective April 1, 2015. The Corporation also obtains pharmaceutical and other products for discounted prices directly from pharmaceutical manufacturers. While the loss of a supplier could adversely affect our business if alternate sources of supply are unavailable, numerous sources of supply are generally available to us and we have not experienced any difficulty in obtaining pharmaceuticals or other products and supplies to conduct our business.

The Corporation seeks to maintain an on-site inventory of pharmaceuticals and supplies to ensure prompt delivery to our customers. Cardinal maintains local distribution facilities in most geographic markets in which we operate.

30

Treasury Stock

In August 2010, the Board of Directors authorized a share repurchase of up to \$25.0 million of the Corporation's common stock, of which \$10.5 million was used. On July 2, 2012 the Board of Directors authorized an increase to the remaining portion of the existing stock repurchase program that allows the Corporation to again repurchase up to a maximum of \$25.0 million of the Corporation's common stock. Approximately \$19.7 million remained available under the program as of September 30, 2015. Share repurchases under this authorization may be made in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and may be funded from available cash or the revolving credit facility. The amount and timing of the repurchases, if any, would be determined by the Corporation's management and would depend on a variety of factors including price, corporate and regulatory requirements, capital availability and other market conditions. Common stock acquired through the share repurchase program would be held as treasury shares and may be used for general corporate purposes, including reissuance in connection with acquisitions, employee stock option exercises or other employee stock plans. The share repurchase program does not have an expiration date and may be limited, terminated or extended at any time without prior notice. During the three months ended September 30, 2015, the Corporation repurchased no shares of common stock.

The Corporation may redeem shares from employees upon the vesting of the Corporation's stock awards for minimum statutory tax withholding purposes and to cover option exercise costs. The Corporation redeemed 156,963 shares from the vesting of certain awards and the exercise of certain stock options, for an aggregate price of approximately \$4.3 million during the nine months ended September 30, 2015. These shares have also been designated by the Corporation as treasury stock.

31

Supplemental Quarterly Information

The following tables represent the results of the Corporation's quarterly operations for the year ended December 31, 2014 and for the first, second and third quarters of 2015 (in millions, except where indicated):

| | 2014 Quarters | | | | 2015 Quarters | | |
|---|---------------|-----------|-----------|-----------|---------------|-----------|-----------|
| | First | Second | Third | Fourth | First | Second | Third |
| Revenues | \$452.2 | \$448.6 | \$470.2 | \$523.5 | \$511.6 | \$497.5 | \$498.8 |
| Cost of goods sold | 372.2 | 366.7 | 387.2 | 429.1 | 423.0 | 416.3 | 420.2 |
| Gross profit | 80.0 | 81.9 | 83.0 | 94.4 | 88.6 | 81.2 | 78.6 |
| Selling, general and administrative | 57.2 | 57.9 | 56.0 | 65.2 | 59.0 | 55.4 | 52.7 |
| Amortization expense | 4.4 | 4.3 | 4.9 | 6.5 | 6.6 | 7.0 | 7.0 |
| Merger, acquisition, integration costs, and other charges | 5.0 | 1.5 | 3.8 | 3.3 | 3.8 | 3.4 | 8.0 |
| Settlement, litigation and other related charges | 1.2 | 26.6 | 1.1 | 8.4 | 2.3 | 6.9 | 2.1 |
| Restructuring and impairment charges | 1.9 | 1.2 | 0.1 | 0.1 | 0.1 | - | 0.2 |
| Hurricane Sandy disaster costs | - | 0.1 | - | (1.8) | - | - | 0.1 |
| Operating income (loss) | 10.3 | (9.7) | 17.1 | 12.7 | 16.8 | 8.5 | 8.5 |
| Interest expense, net | 2.5 | 2.3 | 2.1 | 3.0 | 1.4 | 1.9 | 2.1 |
| Loss on debt extinguishment | - | - | 4.3 | - | - | - | - |
| Income (loss) before income taxes | 7.8 | (12.0) | 10.7 | 9.7 | 15.4 | 6.6 | 6.4 |
| Provision (benefit) for income taxes | 3.0 | (2.3) | 2.2 | 6.5 | 5.8 | 4.3 | 3.4 |
| Net income (loss) | \$4.8 | \$(9.7) | \$8.5 | \$3.2 | \$9.6 | \$2.3 | \$3.0 |
| Earnings (loss) per share (1): | | | | | | | |
| Basic | \$0.16 | \$(0.32) | \$0.28 | \$0.11 | \$0.32 | \$0.08 | \$0.10 |
| Diluted | \$0.16 | \$(0.32) | \$0.28 | \$0.10 | \$0.31 | \$0.07 | \$0.10 |
| Adjusted diluted earnings per diluted share (1)(2): | \$0.37 | \$0.40 | \$0.45 | \$0.45 | \$0.48 | \$0.37 | \$0.39 |
| Shares used in computing earnings (loss) per share: | | | | | | | |
| Basic | 29.8 | 30.0 | 30.1 | 30.1 | 30.2 | 30.4 | 30.4 |
| Diluted | 30.4 | 30.0 | 30.6 | 30.7 | 30.7 | 30.8 | 30.9 |
| Balance sheet data: | | | | | | | |
| Cash and cash equivalents | \$12.7 | \$11.1 | \$7.1 | \$33.3 | \$25.2 | \$21.3 | \$40.0 |
| Working capital (3) | \$273.4 | \$310.3 | \$335.1 | \$319.1 | \$292.8 | \$293.5 | \$285.1 |
| Goodwill (3) | \$282.7 | \$286.9 | \$319.5 | \$323.6 | \$341.9 | \$341.9 | \$341.8 |
| Intangible assets, net | \$131.9 | \$130.4 | \$184.1 | \$177.6 | \$179.2 | \$172.2 | \$165.2 |
| Total assets (3) | \$868.6 | \$922.5 | \$1,045.5 | \$1,074.0 | \$1,044.9 | \$1,062.3 | \$1,060.0 |
| Long-term debt | \$230.9 | \$268.9 | \$360.9 | \$350.7 | \$325.5 | \$349.3 | \$337.4 |
| Total stockholders' equity | \$470.0 | \$462.2 | \$472.7 | \$478.1 | \$487.1 | \$492.1 | \$496.9 |
| Supplemental information: | | | | | | | |
| Adjusted EBITDA(2) | \$29.7 | \$30.6 | \$33.0 | \$37.3 | \$37.4 | \$33.2 | \$33.3 |

Edgar Filing: PharMerica CORP - Form 10-Q

| | | | | | | | | | | | | | | |
|---|----------|---|----------|---|-----------|---|----------|---|----------|---|----------|---|----------|---|
| Adjusted EBITDA Margin (2) | 6.6 | % | 6.8 | % | 7.0 | % | 7.1 | % | 7.3 | % | 6.7 | % | 6.7 | % |
| Adjusted EBITDA per prescription dispensed (2) | \$3.45 | | \$3.64 | | \$3.89 | | \$3.93 | | \$4.13 | | \$3.93 | | \$4.06 | |
| Net cash provided by (used in) operating activities | \$4.4 | | \$(26.5) |) | \$19.7 | | \$50.8 | | \$44.3 | | \$(22.2) |) | \$37.5 | |
| Net cash used in investing activities | \$(16.3) |) | \$(13.6) |) | \$(113.4) |) | \$(13.7) |) | \$(25.0) |) | \$(6.5) |) | \$(6.8) |) |
| Net cash (used in) provided by financing activities | \$0.4 | | \$38.5 | | \$89.7 | | \$(10.9) |) | \$(27.4) |) | \$24.8 | | \$(12.0) |) |
| Statistical information (in whole numbers except where indicated) | | | | | | | | | | | | | | |
| Volume information | | | | | | | | | | | | | | |
| Prescriptions dispensed (in thousands) | 8,608 | | 8,411 | | 8,492 | | 9,491 | | 9,053 | | 8,452 | | 8,208 | |
| Revenue per prescription dispensed | \$52.53 | | \$53.33 | | \$55.37 | | \$55.16 | | \$56.51 | | \$58.86 | | \$60.77 | |
| Gross profit per prescription dispensed | \$9.29 | | \$9.74 | | \$9.77 | | \$9.95 | | \$9.79 | | \$9.61 | | \$9.58 | |
| Gross profit margin | 17.7 | % | 18.3 | % | 17.7 | % | 18.0 | % | 17.3 | % | 16.3 | % | 15.8 | % |
| Generic drug dispensing rate | 84.5 | % | 85.0 | % | 85.1 | % | 84.9 | % | 85.3 | % | 86.0 | % | 86.5 | % |
| Inventory days on hand | 26.0 | | 35.1 | | 31.7 | | 29.1 | | 26.1 | | 29.6 | | 25.7 | |
| Revenue days outstanding | 37.7 | | 37.0 | | 36.7 | | 34.9 | | 34.0 | | 35.4 | | 35.5 | |

(1) The Corporation has never declared a cash dividend. Earnings (loss) per common share in actual cents.

See "Use of Non-GAAP Measures for Measuring Quarterly Results" for a definition and Reconciliation of (2) Adjusted Earnings Per Diluted Common Share to Earnings (Loss) Per Diluted Common Share, and for Reconciliation of Net Income (Loss) to Adjusted EBITDA and Adjusted EBITDA Margin.

(3) As adjusted, see Note 2—Acquisitions in the Condensed Consolidated Financial Statements.

Use of Non-GAAP Measures for Measuring Quarterly Results

The Corporation calculates Adjusted EBITDA as provided in the reconciliation below and calculates Adjusted EBITDA Margin by taking Adjusted EBITDA and dividing it by revenues adjusted for the contractual amount associated with the California Medicaid estimated recoupment. The Corporation calculates and uses Adjusted EBITDA as an indicator of its ability to generate cash from reported operating results. The measurement is used in concert with net income (loss) and cash flows from operating activities, which measure actual cash generated in the period. In addition, the Corporation believes that Adjusted EBITDA and Adjusted EBITDA Margin are supplemental measurement tools used by analysts and investors to help evaluate overall operating performance and the ability to incur and service debt and make capital expenditures. In addition, Adjusted EBITDA, as defined in the Credit Agreement, is used in conjunction with the Corporation's debt leverage ratio and this calculation sets the applicable margin for the quarterly interest charge. Adjusted EBITDA, as defined in the Credit Agreement, is not the same calculation as this Adjusted EBITDA table. Adjusted EBITDA presented herein does not represent funds available for the Corporation's discretionary use and is not intended to represent or to be used as a substitute for net income (loss) or cash flows from (used in) operating activities data as measured under U.S. GAAP. The items excluded from Adjusted EBITDA but included in the calculation of the Corporation's reported net income (loss) and cash flows from (used in) operating activities are significant components of the accompanying condensed consolidated statements of operations and cash flows and must be considered in performing a comprehensive assessment of overall financial performance. The Corporation's calculation of Adjusted EBITDA may not be consistent with calculations of EBITDA used by other companies. The following are reconciliations of Adjusted EBITDA to the Corporation's net income (loss) and net operating cash flows for the periods presented.

The Corporation calculates and uses adjusted diluted earnings per share, which is exclusive of the impact of merger, acquisition, integration costs and other charges, settlement, litigation costs and other related charges, Hurricane Sandy disaster costs, restructuring and impairment charges, stock-based compensation and deferred compensation, loss on debt extinguishment, and impact of discrete items on tax provision ("the Excluded Items") as an indicator of its core operating results. The measurement is used in concert with net income and diluted earnings per share, which measure actual earnings per share generated in the period. The Corporation believes the exclusion of these charges in expressing earnings per share provides management with a useful measure to assess period to period comparability and is useful to investors in evaluating the Corporation's operating results from period to period. Adjusted diluted earnings per share after giving effect to the Excluded Items does not represent the amount that effectively accrues directly to stockholders (i.e., such costs are a reduction in earnings and stockholders' equity) and is not intended to represent or to be used as a substitute for diluted earnings per share as measured under U.S. GAAP. The Excluded Items are significant components of the accompanying condensed consolidated statements of operations and must be considered in performing a comprehensive assessment of overall financial performance. The following is a reconciliation of adjusted diluted earnings per share to the Corporation's U.S. GAAP earnings (loss) per diluted common share for the periods presented.

Edgar Filing: PharMerica CORP - Form 10-Q

Unaudited Reconciliation of Net Income (Loss) to Adjusted EBITDA (dollars in millions)

| | 2014 Quarters | | | | 2015 Quarters | | |
|--|---------------|-----------|--------|--------|---------------|--------|--------|
| | First | Second | Third | Fourth | First | Second | Third |
| Net income (loss) | \$4.8 | \$ (9.7) | \$8.5 | \$3.2 | \$9.6 | \$2.3 | \$3.0 |
| Add: | | | | | | | |
| Interest expense, net | 2.5 | 2.3 | 2.1 | 3.0 | 1.4 | 1.9 | 2.1 |
| Merger, acquisition, integration costs and other charges | 5.0 | 1.5 | 3.1 | 3.3 | 3.8 | 3.4 | 8.0 |
| Settlement, litigation and other related charges | 1.2 | 26.6 | 1.1 | 8.4 | 2.3 | 6.9 | 2.1 |
| Restructuring and impairment charges | 1.9 | 1.2 | 0.1 | 0.1 | 0.1 | - | 0.2 |
| Loss on extinguishment of debt | - | - | 4.3 | - | - | - | - |
| Hurricane Sandy disaster costs | - | 0.1 | - | (1.8) | - | - | 0.1 |
| Stock-based compensation and deferred compensation | 2.1 | 1.8 | 1.8 | 2.3 | 2.0 | 1.7 | 1.7 |
| Provision (benefit) for income taxes | 3.0 | (2.3) | 2.2 | 6.5 | 5.8 | 4.3 | 3.4 |
| Depreciation and amortization expense | 9.2 | 9.1 | 9.8 | 12.3 | 12.4 | 12.7 | 12.7 |
| Adjusted EBITDA | \$29.7 | \$30.6 | \$33.0 | \$37.3 | \$37.4 | \$33.2 | \$33.3 |
| Adjusted EBITDA Margin | 6.6 % | 6.8 % | 7.0 % | 7.1 % | 7.3 % | 6.7 % | 6.7 % |

Unaudited Reconciliation of Adjusted EBITDA to Net Operating Cash Flows (dollars in millions)

| | 2014 Quarters | | | | 2015 Quarters | | |
|--|---------------|------------|--------|---------|---------------|------------|---------|
| | First | Second | Third | Fourth | First | Second | Third |
| Adjusted EBITDA | \$29.7 | \$30.6 | \$33.0 | \$37.3 | \$37.4 | \$33.2 | \$33.3 |
| Interest expense, net | (2.5) | (2.3) | (2.1) | (3.0) | (1.4) | (1.9) | (2.1) |
| Merger, acquisition, integration costs and other charges | (5.6) | (29.4) | (4.3) | (11.8) | (6.2) | (10.3) | (10.4) |
| Provision for bad debt | 5.6 | 5.7 | 5.3 | 6.6 | 5.0 | 3.0 | 1.5 |
| Amortization of deferred financing fees | 0.7 | 0.6 | 0.5 | 0.1 | 0.1 | 0.2 | 0.1 |
| (Gain) loss on disposition of equipment | (0.1) | - | - | - | 0.1 | - | - |
| (Gain) loss on acquisition | (0.3) | - | 0.1 | - | - | - | - |
| Provision (benefit) for income taxes | (3.0) | 2.3 | (2.2) | (6.5) | (5.8) | (4.3) | (3.4) |
| Deferred income taxes | 4.0 | (3.3) | (4.0) | 1.0 | 2.3 | 0.2 | 2.1 |
| Changes in federal and state income tax payable (receivable) | (1.3) | (2.8) | 3.7 | 7.6 | 0.1 | (9.1) | (1.0) |
| Excess tax benefit from stock-based compensation | (2.7) | (0.5) | (0.2) | - | (1.9) | (0.2) | (0.2) |
| Changes in assets and liabilities | (20.2) | (27.4) | (10.1) | 19.1 | 14.6 | (33.1) | 17.6 |
| Other | 0.1 | - | - | 0.4 | - | 0.1 | - |
| Net Cash Flows Provided by (Used in) Operating Activities | \$4.4 | \$ (26.5) | \$19.7 | \$50.8 | \$44.3 | \$ (22.2) | \$37.5 |

Unaudited Reconciliation of Diluted Earnings (Loss) Per Share to Adjusted Diluted Earnings Per Share

| | 2014 Quarters | | | | 2015 Quarters | | |
|--|---------------|------------|--------|--------|---------------|--------|--------|
| | First | Second | Third | Fourth | First | Second | Third |
| Diluted earnings (loss) per share | \$0.16 | \$ (0.32) | \$0.28 | \$0.10 | \$0.31 | \$0.07 | \$0.10 |
| Add: | | | | | | | |
| Diluted earnings per share impact of: | | | | | | | |
| Merger, acquisition, integration costs and other charges | 0.10 | 0.03 | 0.06 | 0.08 | 0.08 | 0.07 | 0.17 |

Edgar Filing: PharMerica CORP - Form 10-Q

| | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|
| Settlement, litigation and other related charges | 0.03 | 0.61 | 0.02 | 0.11 | 0.05 | 0.13 | 0.04 |
| Restructuring and impairment charges | 0.04 | 0.03 | - | - | - | - | 0.01 |
| Loss on extinguishment of debt | - | - | 0.09 | - | - | - | - |
| Hurricane Sandy disaster costs | - | - | - | (0.04) | - | - | - |
| Stock-based compensation and deferred compensation | 0.04 | 0.04 | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 |
| Impact of discrete items on tax provision | - | 0.01 | (0.04) | 0.15 | - | 0.06 | 0.03 |
| Adjusted diluted earnings per share | \$0.37 | \$0.40 | \$0.45 | \$0.45 | \$0.48 | \$0.37 | \$0.39 |

34

Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the reporting period, there have been no material changes in the disclosures set forth in Part II, Item 7a in our Form 10-K for the year ended December 31, 2014.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Corporation has carried out an evaluation under the supervision and with the participation of management, including the Corporation's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Corporation's "disclosure controls and procedures" as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this report. The Corporation's disclosure controls and procedures are designed so that information required to be disclosed in the Corporation's reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms. The Corporation's disclosure controls and procedures are also intended to ensure that such information is accumulated and communicated to the Corporation's management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives, and management necessarily is required to use its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2015, the Corporation's disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed in the reports that the Corporation files and submits under the Exchange Act is recorded, processed, summarized and reported as and when required and such information is accumulated and communicated as appropriate to allow timely decisions regarding required disclosures.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Corporation's internal control over financial reporting during the quarter ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect, the Corporation's internal control over financial reporting.

35

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The information called for by this item is incorporated herein by reference to Note 5 included in Part I, Item 1, Financial Statements (Unaudited) - Notes to Condensed Consolidated Financial Statements.

Item 1A. Risk Factors

Except as set forth below, there have been no material changes in our risk factors from those disclosed in the Corporation's Annual Report on Form 10-K for the year ended December 31, 2014. We encourage you to read these risk factors, together with the risk factor below, in their entirety.

If we fail to comply with the terms of our Corporate Integrity Agreement with the OIG or Memorandum of Agreement with the DEA, it could subject us to substantial monetary penalties or suspension or termination from participation in federal healthcare programs.

In May 2015, the Corporation entered into a five-year corporate integrity agreement ("CIA") with the United States Department of Health and Human Services Office of Inspector General ("OIG") and a Memorandum of Agreement ("MOA") with the Drug Enforcement Agency ("DEA") concurrent with the execution of settlement agreements with the OIG and the DEA settling alleged Controlled Substance Act ("CSA") violations and associated False Claims Act allegations.

The CIA requires the Corporation, among other things to: (i) create procedures designed to ensure it complies with the CSA and related regulations; (ii) retain an independent review organization to review the Corporation's compliance with the terms of the CIA and report to the OIG regarding that compliance; and (iii) provide training for certain Corporation employees as to the Corporation's requirements under the CSA. If the Corporation fails to comply with the terms of the CIA, it may be required to pay certain monetary penalties. The imposition of monetary penalties would adversely affect our profitability. Furthermore, if the Corporation commits a material breach of the CIA, the OIG may exclude the Corporation from participating in federal healthcare programs. Any such exclusion would result in the revocation or termination of contracts and/or licenses and potentially have a material adverse effect on our financial condition, results of operations and business prospects.

The MOA provides for an independent obligation for the Corporation to comply with all requirements of the CSA, specifically relating to the dispensing of scheduled prescription drugs. If the Corporation fails to comply with the terms of the MOA, the DEA may suspend a Corporation's pharmacy's DEA Certificate of Registration and begin an administrative hearing process pursuant to 21 U.S.C. § 824. Any such suspension would prohibit the Corporation's pharmacy from dispensing Scheduled prescription drugs and would lead to the revocation or termination of contracts and/or licenses and potentially have a materially adverse effect on our financial condition, results of operation and business prospects.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In August 2010, the Board of Directors authorized a share repurchase program of up to \$25.0 million of the Corporation's common stock, of which \$10.5 million was used. On July 2, 2012, the Board of Directors authorized an increase to the remaining portion of the existing share repurchase program that allows the Corporation to again repurchase up to a maximum of \$25.0 million of the Corporation's common stock. The Corporation did not repurchase any common stock shares under this program during the nine months ended September 30, 2015.

Additionally, the Corporation may redeem shares from employees upon vesting of the Corporation's stock awards for minimum statutory tax withholding purposes and to cover option exercise costs. The Corporation redeemed 156,963 shares from the vesting of certain awards and the exercise of certain stock options, for an aggregate price of approximately \$4.3 million during the nine months ended September 30, 2015. These shares have been designated by the Corporation as treasury stock.

The following table summarizes our share repurchase activity by month for the three months ended September 30, 2015:

| Period | Total Number of Shares Purchased | Weighted Average Price Paid per Share | Total Number of Shares Purchased as Part of a Publicly Announced Plans or Programs (2) | Approximate Dollar Value of Shares that may yet be Purchased under the Plans or Programs (in millions) |
|--|----------------------------------|---------------------------------------|--|--|
| July 1, 2015 - July 31, 2015 | 277 | (1) \$ 35.28 | - | \$ 19.7 |
| August 1, 2015 - August 31, 2015 | 8,456 | (1) 34.08 | - | 19.7 |
| September 1, 2015 - September 30, 2015 | 3,746 | (1) 31.34 | - | 19.7 |

(1) The Corporation repurchased 12,479 shares of common stock in connection with the vesting of certain stock awards to cover minimum statutory withholding taxes.

On August 24, 2010, the Board of Directors announced a share repurchase program whereby the Corporation is authorized to purchase up to \$25.0 million of the Corporation's common stock, of which \$10.5 million was used.

(2) On July 2, 2012, the Board of Directors authorized an increase to the remaining portion of the existing share repurchase program that allows the Corporation to again repurchase up to a maximum of \$25.0 million of the Corporation's common stock. The Corporation did not repurchase any common stock shares under this program during the nine months ended September 30, 2015.

Item 4. Mine Safety Disclosures

Not Applicable

36

Item 6. Exhibits

Exhibit
No.

- 10.28* Corporate Integrity Agreement, dated May 14, 2015, by and between PharMerica Corporation and the Office of Inspector General of the United States Department of Health and Human Services.
- 10.29* Memorandum of Agreement, dated May 14, 2015, by and between PharMerica Corporation and the United States Department of Justice, Drug Enforcement Administration.
- 31.1* Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2* Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1* Certification of Chief Executive Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2* Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101.INS XBRL Instance Document.
- 101.SCH XBRL Taxonomy Extension Schema Document.
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document.
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document.
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.

*Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PHARMERICA CORPORATION

Date: November 6, 2015 /s/ Gregory S. Weishar
Gregory S. Weishar
Chief Executive Officer and
Director

Date: November 6, 2015 /s/ David W. Froesel, Jr.
David W. Froesel, Jr.
Executive Vice President, Chief
Financial Officer and Treasurer

/s/ Berard E. Tomassetti
Date: November 6, 2015 Berard E. Tomassetti
Senior Vice President and
Chief Accounting Officer

Exhibit Index

| Exhibit No. | Description |
|-------------|--|
| 10.28 | Corporate Integrity Agreement, dated May 14, 2015, by and between PharMerica Corporation and the Office of Inspector General of the United States Department of Health and Human Services. |
| 10.29 | Memorandum of Agreement, dated May 14, 2015, by and between PharMerica Corporation and the United States Department of Justice, Drug Enforcement Administration. |
| 31.1 | Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2 | Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1 | Certification of Chief Executive Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | XBRL Instance Document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |

